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Angiogenesis in NSCLC has been identified as important therapeutic target in 
combination with EGFR TKIs. However, only small incremental advancements have been made 
for the use of angiogenesis inhibitors in NSCLC and it remains elusive why the inhibition of 
VEGF-mediated neovascularization is not therapeutically efficacious. I present experimental 
evidence that a subpopulation of NSCLC cells with EGFR TKI-induced EMT contributes toward 
the attenuation of the response to EGFR TKI therapy. One of the hallmarks of cancer is 
heterogeneity and I have previously demonstrated that tumor heterogeneity within NSCLC cells 
lines harboring EGFR kinase domain mutations gives rise to divergent resistance mechanisms in 
response to treatment. In vivo admix models are instructive in studying intratumoral heterogeneity 
and in elucidating therapeutic responses and tumor-host interactions. While NSCLC cells with 
acquired EGFR TKI resistance and EMT phenotype did not exhibit growth advantage in vitro, a 
50% epithelial EGFR TKI sensitive and 50% mesenchymal EGFR TKI resistant admix provided 
significant growth advantage in vivo assessed by caliper measurement. This preliminary result led 
us to hypothesize that changes in angiogenic growth factor expression during the EMT process 
might lead to the in vivo growth advantage I observed. To test the hypothesis, I utilized the 
Luminex multiplex assay system to quantify secreted growth factors, cytokines, and chemokines 
important in angiogenesis. I have discovered that epithelial EGFR TKI sensitive cells secrete a 
significant amount of VEGF-A and cells with acquired/transient EGFR TKI resistance with an 
EMT phenotype secrete substantial amount of EDN1. Using an in vitro tube formation assay, I 
xiii 
 
showed that secreted VEGF-A and EDN1 in admix conditions work synergistically to promote 
endothelial cell differentiation. Furthermore, this synergistic effect can be attenuated by 
VEGFR2/EDNRA dual inhibition. Surprisingly, ectopic overexpression of EDN1 in EGFR- 
mutated HCC827 cells resulted in significant growth retardation in vivo. Informed by a literature 
search, I hypothesized that the presence of EDN1 in the tumor microenvironment contributes 
positively to EGFR TKI resistance, possibly through the vasoconstrictive property of EDN1. I 
observed that epithelial/mesenchymal admix tumors and ectopic overexpression of EDN1 in 
EGFR-mutated HCC827 cells conferred significantly more resistance to gefitinib in vivo. This 
result led us to hypothesize that EDN1 may reduce MVD in EGFR-mutated NSCLC tumors 
leading to poor EGFR TKI penetrance in vivo. I tested this through CD31 IHC staining and MVD 
calculation. I indirectly tested poor EGFR TKI penetrance by examining phosphorylated EGFR 
and found maintenance of the signal in admix and mesenchymal tumors. Taken together, I suggest 
that inhibition of the EDN1 signaling system may be an important component to a blood vascular-






















Overview of Lung Cancer 
 
Cancer represents one of the largest causes of death within the United States, with 
an estimated one in four deaths attributed to cancer related disease. Among these, lung 
cancer represents the leading cause of cancer-related deaths with 222,500 new cases in 
2017 alone and an estimated 155,870 cases resulting in the death of the patient in the same 
year[1]. Since the late 1980's, incidence of lung cancer has generally decreased although 
this decline has varied among the several histologically defined sub- types. While 
squamous, large and small cell lung carcinoma rates have declined during this period, the 
incidence of lung adenocarcinoma remains stable among male patients and has increased 
among women and shows large racial variances[2]. 
Lung cancer is histologically divided into two main sub-types; SCLC and NSCLC. 
SCLC typically originates in the lung bronchi and is a fast-growing cancer which 
commonly metastasizes early in development and represents approximately 10% of all lung 
cancer cases. NSCLC represents approximately 85-90% of all lung cancer cases and is 
divided into 3 sub-types. Squamous cell carcinoma generally originates within the center of 
the lung and is common among smoking patients. Large cell carcinoma can originate in 
any area of the lung and is characterized as a fast-growing cancer. Adenocarcinoma 





Additionally, adenocarcinoma is most commonly seen in smokers although it is the most 
common type of lung cancer among non- smokers as well[3]. 
Based on the metastatic status of the cancer, lung cancer is typically divided into four 
stages. Stage I is characterized by a small (<3cm) tumor which is localized to one lung. Stage 
II is characterized by a larger tumor (>5cm) which has spread to local lymph nodes. Stage III 
involves a tumor which has spread to distant lymph nodes. Stage IV represents the most 
advanced cases of lung cancer and involves a large tumor (>7cm) which has metastasized to 
both lungs, into pleural effusion or into a different tissue in the body[4]. Stage IV lung cancer 
is commonly referred to as advanced stage or metastatic lung cancer. 
The staging diagnosis is used to determine the treatment regimen for the patient. 
Stage I and stage II lung cancers are most often treated with surgical resection of either the 
affected lobe of the lung or wedge resection. Depending on the risk factor of the resected 
tumor, adjuvant chemotherapy or radiation therapy may be prescribed. Resected tumors are 
commonly tested for the presence of cancer cells at the margins of the section. If positive 
margins are seen, another surgery or chemotherapy is commonly prescribed. Stage III is 
commonly treated with a combination of chemotherapy, radiation therapy and surgery. 
Stage IV lung cancers represent the most difficult to treat since the cancer has achieved a 
large tumor size and metastasized to distant parts of the body. This is also the stage at 
which most cases of lung cancer are diagnosed. These patients are often not eligible for 
surgery or chemotherapy[5]. Therefore, it is important to explore developmental 
therapeutics targeting the specific genetic abnormalities present in the tumor. Although 
these treatments are unlikely to result in life-long remission, any extension of life or 





The discovery of the oncogenic drivers in lung cancers has led to targeted therapies 
which directly target the abnormal signaling pathways which lead to the propagation of 
lung cancer. These therapies have been shown to effectively treat advanced stage lung 
cancers with less risk of side effects compared to traditional chemotherapy. One common 
driver of lung cancer is the RTK EGFR. Mutations in the kinase domain of this receptor 
strongly predicts a poor prognosis and response to drugs which inhibit EGFR[6]. 
EGFR Kinase Domain Mutation in NSCLC 
 
EGFR is a membrane-bound surface RTK. RTKs have been shown to have critical 
roles in normal cell signaling and have also been implicated in the progression of many 
types of cancer[7]. RTKs are a part of the larger family of protein tyrosine kinases which 
includes receptor tyrosine kinases which possess a trans-membrane domain and non-
receptor tyrosine kinases which lack trans-membrane domains[8]. 
EGFR is a member of the ErbB family of receptors. The ErbB family contains four 
related receptor tyrosine kinases: ErbB1 (EGFR), ErbB2 (HER2), ErB3 (HER3) and ErbB4 
(HER4). This family of receptors is known to be over-expressed in several cancers 
including NSCLC and breast cancer. EGFR has been consistently shown to be over-
expressed in 40-80% of NSCLC patients depending on the histological classification of the 
disease[9]. EGFR has been shown to be activated by several ligands including EGF, TGF-
α, amphiregulin, heparin-binding EGF, and betacellulin[10]. Binding of EGFR to its 
ligands results in the homo- or hetero-dimerization with other ERBB family receptors 
leading to internalization and auto- phosphorylation of the receptor by the tyrosine kinase 
domain. Phosphorylated EGFR serves as a scaffold for the binding of signal transduction 





down-stream proteins such as Ras[11]. The MAPK, PI3K, the AKT pathway and the STAT 
pathway represent four major signaling cascades activated by EGFR activation[12]. These 
pathways are known to regulate gene expression, inhibition of apoptosis, angiogenesis and 
cellular proliferation leading to the development of malignancy[13]. Although it was 
originally believed that EGFR signaling was distinct from angiogenesis, a link between 
angiogenesis and EGFR signaling pathways has been described through the EGFR-
dependent stimulation of VEGF-A, a major inducer of angiogenesis[14]. 
A common driver of NSCLC disease is activating kinase domain mutations in 
EGFR which occurs in 10-15% of Caucasian patients and 35% of Asian patients[15], 
KRAS which occurs in 40% of Caucasian patients and 10% of Asian patients[16], or ALK 
which occurs in 7-10% of all NSCLC patients[17]. These mutations cause the cell to 
become dependent on the mutated signaling pathway and renders the tumor exquisitely 
sensitive to inhibition of their respective mutated pathways, a phenomenon known as 
oncogene addiction. In oncogene addiction, pro-apoptotic signaling generally increases as a 
response to increased pro-survival signaling by the mutated oncogenic driver. The use of 
targeted inhibitors results in the removal of oncogenic driver signaling leading to cell death 
through up-regulated pro-apoptotic signaling. This phenomenon is known as oncogenic 
shock[18]. Activating EGFR mutations commonly occur within exons 18-21, which code 
for a portion of the kinase domain. Around 90% of EGFR exon 18-21 mutations consist of 
exon 19 deletions or exon 21 point mutations resulting in a constitutively active 
receptor[19]. The activating mutations commonly seen in EGFR are commonly localized to 
the p-loop, a set of residues which contributes to holding the receptor in the inactive state. 





receptor in the inactive state. Point mutations such as the common L858R or G719S 
substitutions occur within this p-loop and disrupt interactions with the regulatory c-helix. 
This causes the receptor to adopt a conformation similar to the activated wild-type 
receptor. The increased sensitivity of EGFR with activating mutations such as L858R to 
EGFR TKIs has been attributed to increased van der Waals interactions between the drug 
and an aspartic acid residue in position 855. In the wild-type receptor, this residue is 
pointed away from the ATP binding cleft but in the context of a p-loop point mutation such 
as L858R, changes in receptor conformation result in ASP855 being rotated toward the 
ATP binding cleft resulting in stronger binding between the receptor and drug[20, 21]. In 
the more common case of EGFR exon 19 deletions (44% of all EGFR activating 
mutations)[22], residues 746-750 are absent. These residues localize to the regulatory c-
helix domain. The deletion of these residues disrupts the interaction between the c-helix 
and p-loop leading to constitutive EGFR activity by forcing the receptor to adopt a 
conformation similar to the activated wild-type receptor. Like exon 21 point mutations, this 
type of mutation results in an increased affinity for EGFR TKIs and reduced affinity for 
ATP[23]. 
The first drugs to target this pathway were the receptor TKIs gefitinib and 
erlotinib[16]. These drugs are reversible ATP competitive inhibitors and NSCLC cells 
harboring EGFR kinase domain mutations are exquisitely sensitive to the drugs due to their 
oncogene addiction[15]. Furthermore, adverse side effects from the usage of EGFR TKIs has 
been shown to be minimal. In 2004, an evaluation of safety and efficacy of the EGFR TKI 
gefitinib was conducted among 31 Chinese advanced NSCLC patients which had progressed 





administered by a daily oral tablet (250mg) and adverse events were generally mild (grade 1 
or 2) and reversible. The most frequent adverse effects in this study were diarrhea and acne 
form rash. The tumor response rate in this study was 35.5% and the median overall survival 
was 11.5 months[24]. Due to these results and other agreeing studies, gefitinib has been 
approved as a safe and effective treatment for advanced stage NSCLC with positive EGFR 
activating mutations. 
Unfortunately, response to EGFR TKI is not universal. Primary resistance occurs 
through several avenues and acquired resistance can emerge due to secondary mutation 
(T790M) in EGFR[25], the up-regulation of the RTK MET[26], the transformation of 
NSCLC cells into a SCLC phenotype or through EMT[27]. 
Resistance to EGFR TKI Treatment 
 
Primary resistance to EGFR TKI treatment is commonly defined as tumor 
insensitivity during first-line administration of EGFR TKIs. Although the mechanisms 
behind EGFR TKI primary resistance are not well understood, mutations have been 
identified which lower the binding affinity of EGFR toward TKI molecules. The most 
frequent mutations which result in primary resistance are those represented by an exon 20 
insertion. These mutations exist as roughly 1-10% of all EGFR mutations and represent 
mutations within the N-terminus of EGFR (M766 to C775) and most commonly, mutations 
concentrate within the C-helix (A767 to C775) region. This region is important for the 
manipulation of ATP by the kinase domain of EGFR into the correct orientation for 
catalysis. 
Another important mutation implicated in primary EGFR TKI resistance is represented 





the receptor. Interestingly, this mutation prevents EGFR from binding to its ligands such as 
EGF. Although currently debated, it is thought that this mutation results in structural 
changes in EGFR which affect the conformation of the ATP-binding pocket, preventing 
EGFR TKI drug binding. This mutation is present in 5% of SCC and has been shown to 
affect TKI resistance in vitro[28]. 
Primary resistance may not only occur due to mutations in EGFR but also due to 
genetic alterations within EGFR down-stream signaling members. Treatment by EGFR 
TKIs results in the induction of the apoptosis signaling cascade leading to the death of 
the cell[29]. An important pro- apoptotic protein is the Bcl-2 family member, BIM. BIM 
functions by inhibiting anti-apoptotic Bcl-2 family proteins at the mitochondria or by 
activating the pro-apoptotic protein BAX[30]. Patients with BIM deletion mutations or 




Treatment with EGFR TKIs generally elicits a strong response among NSCLC 
patients harboring EGFR activating mutations but drug resistance typically develops within 
6-18 months of treatment[32]. This acquired resistance to EGFR TKIs greatly reduces 
patient progression-free survival in advanced stage NSCLC[33]. It is important to study the 
underlying genetic and expression level changes which occur during the acquisition of 
resistance in order to design treatments which can treat patients with acquired EGFR TKI 
resistance. 
The most common route to acquired resistance is through the T790M mutation in 





cases[25]. This mutation occurs within the ATP-binding pocket of EGFR and results in an 
increased affinity for ATP and a decreased affinity for first-generation EGFR TKIs[25]. In 
2005, a family with a germ line T790M mutation was shown to have a predisposition to 
lung cancer suggesting a possible link between the T790M mutation and tumor growth 
advantage in the absence of selection by EGFR TKI treatment[34]. This predisposition is 
most likely explained by the increased affinity of EGFR harboring T790M for ATP 
resulting in increased EGFR signaling. While the T790M mutation results in decreased 
affinity for first-generation EGFR TKIs such as gefitinib or erlotinib, patients harboring 
this mutation remain sensitive to next-generation irreversible EGFR inhibitors such as 
afatinib or dacomitinib[35]. Clinical trials have been performed with these drugs and 
adverse effects were generally limited to diarrhea and skin rash. While the development of 
these drugs were designed specifically for patients harboring the T790M mutation, the 
response to these drugs in phase II clinical trials was modest compared to first- generation 
EGFR TKIs[36]. Therefore, it has become clear that further research will be required to 
overcome acquired resistance due to the T790M mutation. 
The transmembrane receptor tyrosine kinase MET has also been implicated in 
acquired resistance to EGFR TKI treatment. MET is a single-pass transmembrane tyrosine 
kinase receptor which is important in normal functions such as embryonic development and 
wound healing. The only known ligands for this receptor are HGF and its splice 
variants[37]. Abnormal MET amplification has been shown to correlate with a poor 
prognosis in several cancer types including lung, breast, kidney, liver and brain[38]. MET 
activation by HGF leads to phosphorylation of the tyrosine residues T1234, and T1235. 





feeding into the MAPK, PI3K and STAT signaling pathways leading to increased cell 
growth and survival. In NSCLC, MET amplification has been implicated in approximately 
20% of EGFR TKI resistance cases[39] and therefore represents a major pathway of 
acquired resistance to EGFR TKI therapy. Because of this, several clinical trials have been 
performed with dual EGFR/MET inhibitors as a primary treatment of advanced stage 
NSCLC. In 2010, a phase II clinical trial exploring dual MET/EGFR inhibition using the 
MET inhibitor, ARQ197 and the EGFR TKI erlotinib was performed. PFS was seen to be 
enhanced within patients receiving dual inhibitor treatment and was particularly effective 
in patients with non-squamous histology, K-RAS mutation, and EGFR wild-type status. 
Adverse side effects were not seen to be significantly increased among patients receiving 
dual inhibitor treatment compared to single arm treatment and were limited to rash, fatigue, 
diarrhea and nausea[40]. Although an improvement in patient outcome was seen among 
those receiving dual MET/EGFR inhibitor therapy, escape from drug sensitivity was seen 
among a sub-population of patients implicating other resistance mechanisms as important 
in EGFR TKI insensitivity[40]. 
The ErbB family member HER2 has also been implicated in acquired resistance to 
EGFR TKI treatment. In 2012, Takezawa et al. reported HER2 amplification in 12% of 
tumors with acquired resistance to EGFR TKIs compared to only 1% of untreated lung 
adenocarcinomas[41]. Similar to MET amplification, HER2 amplification has been seen to 
activate the same down-stream signaling cascade as EGFR signaling involving the MAPK, 
PI3K and STAT pathways[42]. With this information, a clinical trial was reported by 
Janjigian et al in 2014 assessing dual therapy using the anti-EGFR antibody Cetuximab and 





EGFR receptors harboring the T790M mutation as well as the HER2 receptor[44]. 
The study showed a similar response rate in patients harboring the T790M mutation 
compared to T790M negative tumors. The authors contributed the similar response rates 
between these two cohorts to HER2 amplification in T790M-negative responding patients 
and identify HER2 as an important target in Afatinib therapy[43]. Therefore, HER2 
amplification has been identified as an important mechanism of acquired resistance in 
EGFR activating mutation positive NSCLC tumors[45]. 
As well as the previously discussed mechanisms, IGF- 1R expression has also 
been shown to be associated with a poor prognosis in NSCLC patients treated with EGFR 
TKIs. Additionally, the expression of IGF-1R has been shown as a negative prognosis 
biomarker in NSCLC patients[46]. Through over-expression and knock out models, it has 
been shown that IGF-1R does not exhibit its prognostic effects through proliferative or 
survival signaling pathways such as the MAPK and AKT pathways respectively[47]. In 
light of this result, alternate pathways must be explored. Recently, Varkaris et al. showed 
a ligand- independent activation of the MET receptor through IGF-1R activation[48]. At 
this point in time, the most supported mechanism of EGFR TKI resistance mediated 
through IGF-1R amplification has been through trans-activation of other relevant 
receptors[49] and may explain why a direct link between IGF-1R expression and EGFR 
TKI resistance has not been shown. 
Aside from genetic mutation, phenotypic-mediated acquired resistance has been 
shown in tumors which have developed acquired resistance to EGFR TKIs. One important 
mechanism has been identified as the histological conversion of NSCLC to SCLC. This 





patient showed tumor response to EGFR TKI therapy for 18 months but following disease 
progression, a second biopsy showed a SCLC histology harboring the original EGFR 
activating mutation[50]. Following this observation, several other cases of NSCLC to 
SCLC transformation have been identified[51, 52]. It has long been understood that 
p53/RB1 loss has an important role in the tumorigenesis of SCLC and one study showed 
that all SCLC tumors tested showed either a mutation or loss of RB1 expression[53]. 
Furthermore, an analysis of repeat biopsy samples acquired from EGFR TKI treated 
NSCLC patients harboring a SCLC conversion showed a 100% rate of RB1[50] loss 
further implicating RB1 loss as an important event in SCLC conversion. 
Taken together, the conversion from a NSCLC histology to a SCLC histology has been 
supported as an important mechanism to acquired resistance to EGFR TKI treatment in a 
subset of NSCLC patients. 
An additional important phenotype-mediated acquired resistance mechanism to 
EGFR TKIs has been shown in tumors harboring a sub-population of cancer cells 
expressing mesenchymal marker proteins such as CD44, N-Cadherin, and Vimentin[27, 
54]. These marker proteins are well known to be up-regulated during EMT and have been 
associated with poor response to EGFR TKI therapy. The EMT process also commonly 
results in cancer cells with increased capabilities for invasion and metastasis as well as 
stem-like properties. It has been shown that the EMT process can be induced in NSCLC 
cell lines by chronic exposure to EGFR TKIs[55]. This process will occur in vitro over an 
approximately 6-month period[55]. This is also the time frame in which acquired EGFR 
TKI resistance occurs in NSCLC patients undergoing EGFR TKI treatment, supporting the 





view, Cao et al. performed a statistical analysis in the CICAMS and TCGA dataset 
correlating EMT signature genes with a significantly worse overall survival[23]. Moreover, 
Uramoto et al. showed that nearly half (44%) of analyzed human EGFR TKI resistant 
NSCLC tumors show a down-regulation of epithelial markers coupled with the up-
regulation of mesenchymal markers[57]. The localization of mesenchymal cells within the 
tumor has been shown to be concentrated within the invasive front of the tumor while cells 
which follow behind typically show epithelial traits and maintain extensive cell-cell 
adhesion properties[58, 59]. Within the tumor mass, it has been proposed that cells which 
maintain an epithelial phenotype secrete EMT-inducing factors to surrounding cells. These 
epithelial cells maintain a sub-population of mesenchymal cells spread heterogeneously 
throughout the tumor[60]. Taken together, these data suggest a link between a 
mesenchymal sub-population and EGFR TKI resistance in NSCLC. 
EMT Overview 
 
Epithelial cells cover the body surface and form the lining of body cavities such as 
the digestive tract and lung alveoli. These surfaces typically contain minimal amounts of 
extracellular matrix and exhibit an apical to basal polarity. Conversely, mesenchymal cells 
make up several different cell types such as osteoblasts, adipocytes and fibroblasts. These 
cells are involved in producing the non-cellular stroma which gives support to other cell 
types. EMT is a process in which an epithelial cell loses its adherens junctions, polarity and 
reorganizes its cytoskeleton[56]. Several transcription factors have been identified as key 
players in this transition including SNAIL, ZEB1 and ZEB2 and bHLH factors[56]. 
Changes in the cytoskeletal complex proteins typically involves the repression of 





expression have been shown to be initiated by a combination of various pathways which 
respond to extracellular cues including TGF-β[61]. Furthermore, expression of TGF-β has 
been shown to be increased upon EGFR TKI treatment[55] providing a strong correlation 
between the induction of EMT and EGFR TKI treatment. When EMT occurs the cell 
becomes more stem-like and frequently demonstrates drug resistance, increased metastasis 
and invasiveness[62]. Cells which have undergone EMT typically show reduced expression 
of EGFR as well as its ligands and typically express other RTKs such as AXL[27]. Because 
of these changes in expression lead to EGFR TKI resistance, EMT has been identified as an 
important process in the development of drug resistance and the associated up-regulated 
receptors have been identified as targets in alternative therapies. 
Endothelin-1 Overview 
 
Endothelial cells form a single-celled lining of the inner wall of the blood vessel. It 
was originally believed that these cells simply form a barrier separating blood from 
vascular smooth muscle cells. With the discovery of EDRF, a new avenue of vascular 
research was opened focusing on the signaling capability of the endothelium. Years later, a 
potent vasoconstriction-inducing peptide was isolated from bovine endothelial cell culture 
supernatant and was termed EDN1. Soon after this discovery, two other isoforms of 
endothelin were discovered and termed EDN2 and EDN3. The endothelins were originally 
thought to work systemically to affect blood pressure although it was later found that 
circulating endothelin levels are quite low and the peptide acts primarily as a local 
hormone. Beyond its effect on vasoconstriction it was found that endothelin can also act as 
a mitogen for endothelial cells and vascular smooth muscle cells[63]. Because of this 





as a factor which can induce the proliferation of endothelial and smooth muscle cells. 
The endothelin signaling axis has been implicated not only in NSCLC[64] but in 
other cancers such as colorectal and kidney cancer and the expression of the ligand EDN1 
and the EDNRA expression has been linked to poor survival outcomes and increased disease 
progression in these cancers[65, 66]. The endothelin signaling system consists of three 
different peptides, EDN1, EDN2, and EDN3 and their two receptors EDNRA and EDNRB 
which belong to a family of GPCRs. EDNRA shows similar affinities for EDN1 and ET-2 
but a 100-fold reduction in affinity for ET-3. Conversely, EDNRB shows a similar affinity 
for EDN1, EDN2 and EDN3[67]. EDNRA, EDNRB and EDN1 have been shown to be 
commonly up-regulated in multiple cancer types[68, 69] and therefore I hypothesize that 
EDN1 is exerting an effect on NSCLC cells and endothelial cells through EDNRA or 
EDNRB. The activation of EDNRA has been shown to result in the activation of several 
pathways including the mitogen activated protein kinase (MAPK), the PI3K, and PKB 
pathways[70]. The activation of these pathways is known to increase the proliferation, cell 
growth, and survival[71]. The activation of the EDNRA receptor has also been linked to the 
activation of the non-receptor tyrosine kinase, SRC[72]. SRC has many targets within the 
cell and the activation of SRC can result in the activation of RTKs such as the VEGFR1[73], 
and EGFR[74]. These receptors canonically stimulate the MAPK, PI3K and PKB pathways 
increasing cell proliferation, growth and survival[75, 76]. Furthermore, the inhibition of SRC 
has been linked to increased E-cadherin expression and the inhibition of EMT[126]. Because 
of these previous observations, I identified the endothelin signaling axis as a worthwhile 






EDN1 and Vasoconstriction 
 
Of the discovered endothelins, the effects of EDN1 have been most thoroughly 
characterized and seen to be the most active. The role of EDN1 in normal pulmonary 
function is to maintain basal vascular tone. In general, it is understood that the activation of 
the KATP channel inhibits pulmonary vasoconstriction. Through the EDNRA receptor on 
smooth muscle cells, EDN1 has been shown to inhibit the activation of the KATP channel 
leading to pulmonary vasoconstriction. Additionally, EDN1 has been shown to be up-
regulated during hypoxic pulmonary vasoconstriction and causes a vasoconstrictive effect 
both in vitro and in vivo[77]. Following these observations, EDNRA blockade has been 
explored for controlling vasoconstriction in humans[78]. 
The progression of human pulmonary arterial hypertension is known to result from 
the occlusion or vasoconstriction of pulmonary vessels leading to progressive right 
ventricular failure[79]. Several clinical trials have been conducted examining the effect of 
EDNRA antagonists in a pulmonary arterial hypertension model. Recently, Galie et al. 
showed that the addition of the EDNRA antagonist Ambrisentan to standard tadalafil-
monotherapy resulted in a significantly lower risk of clinical-failure events (50%) 
compared to tadalafil or Ambrisentan monotherapy[80]. Tadalafil functions by inducing 
nitric-oxide release in endothelial cells through PDE5 inhibition leading to 
vasodilation[81]. The increased efficacy seen in the Galie trial was attributed to the 
additive effect of inducing vasodilation with tadalafil and inhibiting vasodilation with 
Ambrisentan[80]. 
While EDN1 signaling has been thoroughly explored in cardiovascular disease[80] 





Boldrini et al. showed that expression of EDN1 was related to a poor prognosis in NSCLC 
patients[64] although the mechanism behind this remains unexplored. EDN1 signaling has 
previously been shown to have a pro-angiogenic effect on cultured HUVEC cells and has 
been shown to enhance the pro-angiogenic effect of VEGF in vitro[82, 83]. It would 
therefore be expected that EDN1 expression in vivo would correlate with greater 
angiogenesis and therefore tumor growth. This has proven to be the case in several tumor 
types including ovarian carcinoma[69] and chondrosarcoma[84]. Surprisingly, anti-
neovascularization exerted by EDN1 has also been reported in other cancer types such as 
castration-resistant prostate cancer[85] and some melanomas[86]. The decreased tumor 
growth in these cancers were attributed to the vasoconstrictive properties of EDN1 
preventing sufficient blood flow to the tumor. Furthermore, it has been shown that 
retarded tumor growth in castration-resistant prostate cancer over-expressing EDN1 can be 
abrogated by treatment with vasodilators further implicating EDN1-mediated 
vasoconstriction in obstructing tumor growth[85]. It is therefore an aim of this study to 
explore whether EDN1 shows a pro-angiogenic or anti-angiogenic effect on tumor growth 
in NSCLC. Commonly, tumor neo-angiogenesis is evaluated by calculation of MVD 
within the tumor. I will utilize this technique to evaluate tumor neo-angiogenesis in a 
NSCLC model. 
VEGF Signaling Overview 
 
The VEGFs are the principal regulators of blood vessel growth and function in 
adulthood. These signaling peptides consist of 5 members: VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, and PlGF. These members exist primarily as homodimers although a heterodimer 
between VEGF-A and PlGF has been reported[87]. VEGF-A was originally described by 





family proteins is further expanded through alternative splicing. For example, VEGF-A is 
naturally found in 4 isoforms, VEGF121, VEGF145, VEGF165, and VEGF189. These isoforms 
show differential ability to bind ECM components such as heparin sulfate and determine 
the level of VEGF-A retention at the cell surface or ECM[89]. The expression of VEGF-A 
is regulated by HIF-1α, leading to increased expression in hypoxic environments[90]. 
 
VEGF-A primarily interacts with the receptor VEGFR2. VEGFR2 is a RTK family 
protein with an extracellular ligand binding domain and an intracellular tyrosine kinase 
domain connected by a single transmembrane domain. Like other RTKs, VEGF-A binding 
to VEGFR2 induces homo- or hetero-dimerization leading to auto-phosphorylation of the 
intracellular domain, allowing the phosphorylated protein complex to act as a scaffold for 
the binding of down-stream signaling members[91]. VEGFR2 plays an essential role in 
angiogenesis in both normal development and tumorigenesis. Shalaby et al. showed that 
VEGFR2-/- mice die at E8.5 due to impaired hematopoietic and endothelial cell 
development[92]. Several inhibitors of VEGFR2 have been tested in clinical trials with the 
aim of inhibiting blood vessel development in the context of cancer-related disease. A 
phase II clinical trial was conducted with the VEGFR2 inhibitor, ramucirumab. 140 
patients with recurrent or advanced stage NSCLC were given ramucirumab as an adjuvant 
treatment with traditional chemotherapy. Hypertension was reported as the primary adverse 
effect. The median progression free survival was recorded as 6.5 months in patients 
receiving adjuvant ramucirumab compared to 4.3 months in patients receiving 
chemotherapy alone[93]. While modest improvements in patient prognosis was common 
across these clinical trials, the promise of VEGFR inhibitor therapy has largely failed to 





Given that angiogenesis is a hallmark of several types of progressive tumors, VEGF 
signaling has been implicated as a potential therapeutic target. Overexpression of the 
VEGFs has been found in most human cancers including NSCLC. The expression of 
VEGFs in NSCLC has been linked to increased tumor recurrence, metastasis and death. 
The angiogenic phenotype associated with VEGF expression is considered a hallmark of 
malignancy in which increased tumor neo-angiogenesis provides a pathway to metastasis 
and increased tumor growth rate[94]. Because of this, the VEGF signaling pathway has 
been examined in NSCLC disease progression. To date, two antiangiogenic agents, 
bevacizumab and ramucirumab have been approved for the treatment of advanced or 
metastatic NSCLC as adjuvant therapy to standard first-line chemotherapy[95]. These 
monoclonal antibodies target VEGF or its receptor VEGFR2 respectively. Small molecule 
inhibitors of VEGFR2 have also been explored in targeting angiogenesis in NSCLC 
although these drugs to date have largely failed to improve patient outcome compared to 
first-line chemotherapy. The multi-target inhibitor, nintedanib, in combination with the 
chemotherapy agent docetaxel, is the exception to this rule. Nintedanib targets not only 
VEGF, but also PDGF and FGF signaling pathways and effectively reduces tumor neo- 
angiogenesis and improves overall survival in patients with advanced or metastatic 
NSCLC[96]. This result has generated interest in targeting VEGF signaling with other 
targeted therapy such as EGFR TKIs[97]. 
EGFR TKI Plus VEGFR2 Inhibition in the Clinic 
 
Because tumor neo-angiogenesis is strongly mediated by VEGF-A/VEGFR2 and 
EGFR signaling strongly mediates tumorigenesis and disease progression[98-101], several 





in advanced stage NSCLC patients. The benefit of this treatment was seen to vary between 
studies. A phase II clinical trial was performed with the dual EGFR/VEGFR2 inhibitor 
vandetanib[102]. The aim of the study was to examine if dual EGFR/VEGFR2 inhibition 
could increase the rate of pleurodesis in advanced stage NSCLC patients. The production 
of pleural effusion has been identified as a marker of advanced stage NSCLC and a 
common treatment is the insertion of a pleural catheter for the draining of the pleural 
cavity. VEGF has also been implicated as an important signaling molecule in the 
production of pleural effusion. Because of this, VEGF signaling inhibition was examined 
as a potential way to target pleural effusion production. While the administered daily oral 
dose of 300mg vandetanib was well tolerated among patients, the treatment did not 
significantly decrease the time to pleurodesis[103]. 
A phase II clinical trial was reported in NSCLC patients which have progressed 
after responding to treatment with either gefitinib or erlotinib using the dual 
EGFR/VEGFR2 inhibitor, XL647. Patients received a daily oral dose of 300mg XL647 
throughout the course of the study. A 3% response rate was seen in this study with only 
one patient in the trial showing a significant response to the treatment. Patients with a 
T790M mutation showed a significantly worse progression-free survival rate and the one 
patient which showed a response lacked a T790M mutation. The responding patient 
eventually progressed after 8 months of XL647 treatment. Since the 3% response rate did 
not meet the pre-specified threshold for recommended further study, XL647 was deemed 
unfit for patients which have progressed following gefitinib or erlotinib treatment[104]. 
Another phase II clinical trial was reported comparing the response to the EGFR TKI 





NSCLC patients. Patients admitted into the study were those that had progressed after 
receiving platinum-based chemotherapy. Patients received either 37.5 mg/day sunitinib plus 
150mg/day erlotinib or placebo plus erlotinib. In the 132 randomly assigned patients, the 
median PFS was 2.8 months in patients receiving the combination therapy compared to 2.0 
months in those receiving erlotinib plus placebo and the overall survival was 8.2 months 
compared to 7.6 months. The combination treatment was generally well-tolerated although 
common adverse events such as diarrhea, rash and fatigue was seen at a greater frequency 
among patients receiving the combination treatment. The study concluded that the 
combination sunitinib/erlotinib therapy did not significantly increase the PFS compared to 
erlotinib alone[105]. 
To date, no clinical trials have been conducted examining the benefit of 
VEGFR2/EDNRA dual inhibition therapy. It is therefore important to explore how the 








MATERIALS AND METHODS 
Cell Lines and Cell Culture 
 
HCC4006 cells were obtained from ATCC.org (ATCC CRL-2871). HCC4006 
harbors a mutation (L747 - E749 deletion, A750P) in the EGFR tyrosine kinase domain 
which prevents the regulation of EGFR activation. The cell line was established from a 50+ 
year old Caucasian male with an adenocarcinoma through the collection of pleural 
effusion. Cells show a population doubling time of 41 hours cultured in RPMI-1640 
medium (ATCC 30-2001) supplemented with 10% FBS. 
HCC4006 Ge-R cells with a mesenchymal phenotype were produced from epithelial 
HCC4006 cells by former members of the Shimamura lab by exposing HCC4006 cell to 
increasing concentrations of the EGFR TKI gefitinib over a 6 month period to a final 
concentration of 10μmol/L resulting in a polyclonal EGFR TKI resistant cell line. EGFR 
TKI resistance was confirmed by measuring cell viability after allowing cells to grow in 
gefitinib-free media for 7 days followed by gefitinib treatment. Cells were then cultured 
without drug and resistance to gefitinib was measured periodically[55]. Cells presented a 
mesenchymal phenotype as shown by Western blot of common mesenchymal markers[56]. 
HCC827 cells were obtained from ATCC.org (ATCC CRL-2868). HCC827 





prevents the regulation of EGFR activation. The cell line was isolated from the lung of a 
39 year old caucasian female with an adenocarcinoma. Cells show a population doubling 
time of 28 hours cultured in RPMI-1640 medium (ATCC 30-2001) supplemented with 5% 
FBS. 
ER23 cells were produced in a similar manner as HCC4006 Ge-R cells by previous 
members of the Shimamura lab. HCC827 cells were exposed to increasing concentrations 
of the EGFR TKI erlotinib up to a final concentration of 10μmol/L. Clones were isolated 
and were able to proliferate normally in the presence of 10μmol/L erlotinib. EGFR TKI 
resistance was confirmed by measuring cell viability after allowing cells to grow in 
erlotinib-free media for 7 days followed by erlotinib treatment. Cells were then cultured 
without drug and resistance to erlotinib was measured periodically[55]. Cells presented a 
mesenchymal phenotype as shown by Western blot of common mesenchymal markers[56]. 
The 293LTV cell line was established from primary embryonic human kidney and 
transformed with human adenovirus type 5 DNA. The genes encoded by the E1 region of 
the adenovirus construct are expressed in these cells and allow for high protein production. 
This cell line also expresses the SV40 large T antigen and Neomycin resistance genes 
allowing for stable high-volume production of lentiviral particles[106]. 293LTV cells were 
routinely cultured in 10% FBS DMEM supplemented with 1000μg/mL ABAM and 
1000μg/mL G418. 
HUVEC were obtained from Lonza (Lonza Group, CC-2935). HUVEC cells are 
primary cells derived from a single donor from the resected endothelium of umbilical 
cord veins. HUVEC cells were expanded in EGM media (Lonza Group, CC-3024, CC- 





rinsing cells with Lonza HEPES buffered saline solution (Lonza Group, CC-5022). 
Trypsin/EDTA (Lonza Group, CC-5012) was introduced to the culture flask and allowed 
to sit at 37°C for 3-5min. After cells have detached, trypsin was neutralized with Trypsin 
Neutralizing Solution (TNS, Lonza Group, CC-5002). Multiple frozen aliquots of early 
passage (passage 2) HUVEC cells were prepared following trypsinization by freezing in 
80% EGM media, 10% DMSO, and 10% FBS and stored in liquid nitrogen. 
Luminex Multiplex Assay 
 
The Luminex human angiogenesis/growth factor magnetic bead panel 1 kit 
(Millipore Sigma, HAGP1MAG-12K) was used to perform immunoassay analysis on 
conditioned media prepared as previously described. In a 96-well plate, wells are rinsed 
with assay buffer and 25μL of standards or conditioned media was added to each well 
along with 25uL of assay buffer. 25μL of mixed beads were added to each well and 
allowed to incubate at 2-8°C overnight (16-20 hours) with agitation on a plate shaker. With 
the plate on a magnetic base (Millipore Sigma, #40-285), well contents are removed by 
decanting followed by 3 cycles of washing using 200uL of wash buffer in each well. 25μL 
of detection antibodies were then added to each well and incubated with agitation for 1 
hour at room temperature. 25uL streptavidin-phycoerythrin was then added to each well 
and allowed to bind for 30 minutes at room temperature. Well contents were then washed 3 
times as previously described and 100μL sheath fluid was added to each well. The plate 
was then analyzed on the Luminex FM3D running xPONENT® for FlexMAP™ 3D 
version 4.0.846.0 SP1. Statistical significance was calculated using a one way ANOVA test 
with a post hoc Student's t-test. A heatmap was produced from the resulting data using the 





differences in expression were displayed for each analyte independently. 
Cell Counting 
 
All cell counting was performed using the Countess automated cell counter 
(Thermo Fisher Scientific, 10227). Detached cells were mixed with trypan blue at a 1:1 
ratio and 10uL was pipetted to a Countess cell counting chamber slide (Thermo Fisher 
Scientific, C10228). Live cell count was used for seeding calculations. 
Lentiviral Production and Transduction 
 
293LTV cells were thawed from liquid nitrogen storage and seeded onto a Nunc T-
75 flask (Cat # 156499) in DMEM containing 10% FBS, 1000μg/mL G418, and 
1000μg/mL ABAM. 48 hours prior to transfection, media was changed to antibiotic-free 
DMEM containing 10% FBS. On the day of transfection, the following reagents were 
combined in a sterile microtube: 4μg pLKO plasmid (target or control), 4μg ΔR8.2 
plasmid, 0.5μg VSV-G plasmid. Final volume was brought to 176μL with Opti-MEM and 
24μL TransIT-LT1 was added and gently pipetted to mix bringing the final volume to 
200μL. Mixture was incubated at room temperature for 20-30 minutes. 293LTV cells were 
trypsinized and 1×106 cells were seeded onto 60mm Corning BioCoat Collagen coated 
plates. The mixture from the previous step was added drop-wise onto 293LTV cells and 
gently rocked to mix. Plates were allowed to incubate at 37° C overnight. Media was 
replaced with 3mL 10% FBS RMPI containing 0.58% BSA (20g/100mL +Ca2+/+Mg2+ 
PBS) and plates were allowed to incubate at 37° C for 72 hours. Cell culture supernatant 
was collected and plates were flash frozen with LN2, allowed to thaw and cell debris and 
any remaining viral particles were added to the collected supernatant. Supernatant was 





0.45μM pore SFCA membrane (Nalgene, 723-2545). Viral supernatant was stored at 4° C 
and used for transduction within a week of the production. 24 hours prior to transduction, 
target cells were seeded at 8×105 cells/plate in a 60mm plate to achieve 70-80% confluency 
at the time of transduction including an extra plate for mock transduction. Virus containing 
supernatant was mixed at a 1:1 ratio with appropriate target cell culture media and target 
cell media was replaced with this mixture. Polybrene (Santa Cruz Biotechnology, SC-
134220) was added directly to the plate at a final concentration of 5μg/mL for HCC4006 
cells and HCC4006 derived cells or 10μg/mL for HCC827 cells and HCC827 derived cells. 
Media was replaced with the target cell media/virus containing supernatant every 24 hours 
until 3 rounds of transduction was achieved. Following transduction, virus containing 
media was removed and plates were washed twice with +Ca/+Mg DPBS and plates were 
incubated at 37° C for 24 hours in proper culture media. After 24 hours, media was 
changed with proper cell culture media and proper selection agent concentration was 
increased until cells which underwent mock transduction died. The selection agent used for 
HCC827 EDN1 over-expression models was blasticidin and the concentration was 
increased to a final concentration of 5μg/mL. The selection agent used for HCC4006 Ge-R 
shEDN1 knockdown model was puromycin increased to a final concentration of 5μg/mL. 
Transduction was considered complete when all mock transduction cells died and final 










shRNA Sequences Used 
 
Target RNAi consortium number sequence Remarks 
EDN1 TRCN0000003847 5’ – GCAGTTAGTGAGAGGAAGAAA – 3’  
Non-Target N/A 5’ – GCGCGATAGCGCTAATAATTT – 3’ Sigma SHC- 
 
002 
    
Table 1: List of shRNA sequences used in study. shRNA knockdown and viral transduction 
and infection were performed as previously reported[55]. 
 
 
Conditioned Media Preparation 
 
HCC4006, Ge-R, HCC827, and ER23 cells were seeded onto 6-well plates at 
3×105 total cells/well as a pure culture or admix. 24H after seeding, media was replaced 
with 1.5ml of the proper culturing media based on cell type. Cells were allowed to grow 
at 37° C for 48 hours. Conditioned media was collected after 48h and centrifuged at 400g 
for 10 minutes to remove cellular debris. Cell culture supernatant was collected and flash 
frozen in liquid nitrogen and stored in liquid nitrogen until assayed. Cells were lysed 
using 1x Cell Lysis Buffer (Cell Signaling Technology, 9803S). Cell lysates were 
analyzed for total protein concentration by BCA (Thermo Fisher Scientific, 23225) and 
calculated values were used to normalize measured cell culture supernatant target protein 
concentrations. 
In vitro Angiogenesis 
 
An in vitro tube formation assay was performed according to manufacturer’s 
recommendations. Briefly, ibidi µ-slide angiogenesis plate (ibidi, 81501) was coated with 10 
µL of reduced growth factor Matrigel (Corning, 356231) and allowed to solidify for 30 





counted and 50 µL of cell suspension containing 7500 cells was added to each well 
containing Matrigel matrix. For conditioned media assays, HUVEC cells were suspended in 
the respective conditioned media such that 50 µL of suspension contained 7500 cells and 
added to each well containing Matrigel matrix. The slides were then incubated at 37ºC with 
5% CO2 for 8 hours. Following incubation, Calcein AM (Thermo Fisher Scientific, C1430) 
was added directly to each well to a final concentration of 1µM. Slide was allowed to 
incubate at 37ºC with 5% CO2 for 10 minutes. Tube formation was captured by taking 
fluorescent images with an Evos FL Cell Imaging System (Thermo Fisher Scientific, 
AMF4300) with the GFP channel. Negative controls for all tube formation were performed 
in EBM (Lonza Group, CC-3121) which contains proper salt and pH levels for endothelial 
cells but lacks any pro-angiogenic growth factors. Positive controls in all tube formation 
assays were performed in complete EGM (Lonza Group, CC-3024) which contains the pro-
angiogenic growth factors hEGF, VEGF-A, R3-IGF-1, hFGF-β, Heparin, and FBS at 
manufacturer recommended concentrations. 
Image Analysis 
 
Tube formation images were analyzed using the ImageJ Angiogenesis Analyzer 
plugin provided as free software from the Gilles Carpentier Research Group[107]. The 
parameters measured include total tubule length, mesh area and number of nodes. 
Western Blot Analysis 
 
Protein concentrations were determined by the Pierce BCA Protein Analysis Kit 
(Thermo Fisher Scientific, 23225). Non-specific binding was blocked with 5% nonfat milk 
and incubated with primary antibodies proteins of interest, E-Cadherin (Cell Signaling 





Technology, 3578), actin (Cell Signaling Technology, 8457) and EDNRA (Novus, NB600-
836). The membranes were then washed in PBS plus 0.1% Tween-20 and incubated with 
HRP-conjugated goat anti-rabbit antibody (Cell Signaling Technology, 7074S). The 
membrane was then developed with ECL reagent (Pierce, 32106) and exposed on CL-
Xposure film (Thermo Scientific, 34089). 
Murine Xenograft 
 
All animal studies were done in accordance with IACUC guidelines under the IACUC 
application “Testing Therapeutic Compounds in NSCLC” (LU # 207437). Approximately 
5×106 total cells were injected sub-cutaneously into both right and left flanks of mice. The 
mice were treated (oral gavage) with gefitinib (50mg/kg) daily. Tumor dimensions were 
measured via external caliper measurement thrice weekly and tumor volume was calculated 
(TV=(width)2 X length/2). 
IHC Sample Preparation 
 
Murine xenograft tumors were flash frozen in OCT compound (Tissue-Tek, 4583) and 
stored at - 80°C until sectioning. Sections were prepared using a Cryostar NX50 OP 
cryostat (MICROM International GmbH) to prepare sections of 5µM thickness. Sections 
were mounted on Superfrost™ Plus Gold slides (Thermo Fisher Scientific, 
FT4981GLPLUS). Slides were returned to -80°C and stored until staining. 
Immunohistochemical Staining 
 
IHC staining was performed following the recommended protocol provided by Cell 
Signaling Technologies for frozen tissues. Briefly, 5µM thick sections were fixed for 15 
minutes in 3% formaldehyde at room temperature. Slides were washed in wash buffer (1X 





H202 diluted in methanol. Slides were washed twice for 5 minutes in wash buffer followed 
by incubation in blocking solution (1X TBS/0.3% Triton-X 100/5% normal goat serum). 
Blocking solution was removed and immediately replaced by primary antibody specific to 
the protein of interest at 1:50 dilution in blocking solution and allowed to incubate at 4°C 
overnight. Antibodies used included those targeting total EGFR (Cell Signaling Technology, 
4267), E-Cadherin (Cell Signaling Technology, 3195), CD44 (Cell Signaling Technology, 
3578) and phosphorylated EGFR (Cell Signaling Technology, 2237). Antibody was removed 
and slides were washed in wash buffer 3 times for 5 minutes each. Biotinylated secondary 
antibody was added to each slide diluted 1:100 in blocking solution and allowed to incubate 
for 30 minutes. ABC reagent (Vectastain, PK-6100) was prepared according to 
manufacturer's specifications and allowed to stand at room temperature for 30 minutes before 
use. Slides were washed in wash buffer 3 times for 5 minutes each followed by 30 minute 
incubation in ABC reagent at room temperature. ABC reagent was removed and slides 
washed in wash buffer for 3 times for 5 minutes each. DAB substrate was prepared according 
to manufacturer's recommendation and added to each slide. Slides were allowed to develop for 
2 minutes before being submersed in dH2O. Slides were counterstained with Hematoxylin per 
manufacturer's recommendations. Slides were washed in dH2O twice for 5 minute each. Slides 
were incubated in 95% ethanol twice for 10 seconds each. Slides were then incubated in 
100% ethanol twice for 10 seconds each then repeated in xylene twice for 10 seconds each. 
Coverslips were mounted using Permount Mounting Medium (Thermo Fisher Scientific, 
SP15-500) and slides were allowed to dry overnight prior to imaging. Representative images 







Microvessel Density Determination 
 
MVD was determined by the “hot spot” method to count endothelial cell-lined blood 
vessels[85, 108-110]. Briefly, areas of highest microvessel density were determined to 
calculate the average of 3 fields/section in two tumors/condition, Field=0.16mm2 at 200x. 
CD31 was used as a marker for endothelial cells because it has been shown to be the best 
marker for blood vasculature in benign and malignant tumors[111]. Since CD31 is also 
expressed on platelets, macrophages, neutrophils and monocytes, I exclude any single cells 
staining positive for CD31. Any CD31+ cell clusters, clearly separated from adjacent 
microvessels, tumor tissue, or other tissue elements were considered as a single countable 
microvessel[108]. Images were randomized prior to manual counting in order to reduce bias. 
Fields with MVD closest to the average was displayed as representative images. Significance 














Induction of EMT in EGFR Mutation-Positive NSCLC Cell Lines 
 
I began by ensuring the epithelial or mesenchymal status of the cell lines to be 
used in our study. I found that the expression of the canonical epithelial cell marker E-
Cadherin was down- regulated in HCC4006Ge-R mesenchymal cells compared to 
epithelial HCC4006 cells, whereas canonical mesenchymal cell markers N-Cadherin and 
CD44 were up-regulated (Figure 1A). Similarly, E-Cadherin expression was down-
regulated in mesenchymal ER23 while N-Cadherin and CD44 were up-regulated (Figure 
1B). Additionally, E-Cadherin depletion using lentiviral shRNA efficiently down- 











Figure 1. Induction of EMT in EGFR Mutation-Positive NSCLC Cell Lines. A) Epithelial HCC4006 to mesenchymal 
HCC4006Ge-R comparing epithelial marker E-Cadherin to mesenchymal markers N-Cadherin and CD44. B) Epithelial 
HCC827 to mesenchymal ER23 comparing epithelial marker E-Cadherin to mesenchymal markers N-Cadherin and CD44. 
C) Epithelial HCC827 ΔNT to mesenchymal HCC827 ΔCDH1 comparing epithelial marker E- Cadherin to mesenchymal 





Admix of Epithelial HCC827 and Mesenchymal ER23 Cell Types Confers a Growth 
Advantage In Vivo but No Growth Advantage is Seen in Epithelial and 
Mesenchymal Admix In Vitro in Multiple Cell Lines 
Soucheray et. al. showed that chronic EGFR inhibition in EGFR mutated NSCLC 
cells promoted acquired EGFR TKI resistance with a mesenchymal phenotype[55]. To 
develop novel therapeutics against the EGFR TKI resistant mesenchymal NSCLC cells, 
our laboratory attempted developing xenograft models of the mesenchymal cells. 
However, the growth of the mesenchymal NSCLC cells was significantly impaired in 
vivo. Together with our collaborators, I have found that the mesenchymal NSCLC cells 
need to be mixed with epithelial cells for optimal growth in vivo. Therefore, I wanted to 
study why epithelial and mesenchymal cell populations need to be mixed for the optimal 
in vivo growth. To this end, a subcutaneous xenograft was performed, in which epithelial 
HCC827 or mesenchymal ER23 cells were injected as a pure culture or in a 50/50 admix 
sub- cutaneously in an immunologically deficient murine model. I observed that 
epithelial HCC827 cells successfully established a tumor in all injections. As I have 
previously seen, mesenchymal ER23 cells only established tumors in 80% of injections, 
and produced tumors of very limited volume (Fig.2A). Notably, a 50/50 
epithelial/mesenchymal admix successfully established tumors in all injections and 
exhibited a greater tumor volume at the termination of the experiment compared to 
epithelial tumors (p<0.001) or mesenchymal tumors (p<0.0001). Based on this result, I 
hypothesized that epithelial and mesenchymal cells are programmed to contribute to each 
other for optimal tumor growth. To test the hypothesis, I have mixed epithelial HCC827 





HCC827 cells initially grow faster than mesenchymal ER23 cells, no significant 
difference in proliferation was observed at the end of a 6 day growth period in vitro. The 
50/50 admix conditions produced no significant advantage in cell proliferation compared 
to HCC827 or ER23 pure cultures at the end of a 6 day growth period (Figure 2B). To 
ensure that the in vitro result is not cell lineage specific, I repeated the same in vitro 
experiment using epithelial HCC4006, mesenchymal Ge-R or a 50/50, 70/30 or 30/70 
admix. I observed that all admix conditions failed to produce a significant growth 





































Figure 2. Admix of Epithelial HCC827 and Mesenchymal ER23 Cell Types Confer a Growth Advantage In Vivo but No Growth 
Advantage is Seen in Epithelial and Mesenchymal Admix In Vitro in Multiple Cell Lines. A) Subcutaneous xenograft of a 50/50 admix of 
epithelial HCC827 and mesenchymal ER23 cells demonstrate a growth advantage in vivo compared to pure epithelial (p<0.001) or mesenchymal 
xenografts (p<0.0001). B) 2-D co-culture of epithelial HCC827 and mesenchymal ER23 cells do not result in a growth advantage in vitro. 
Significance was determined by two-way ANOVA with a post hoc student's t-test. C) 2-D co-culture of epithelial HCC4006 and mesenchymal 








HCC827/ER23 50/50 Admix at Time of Implantation Results in an Epithelial 
Dominated Tumor at 24 Days 
E-Cadherin has been identified as a reliable marker of epithelial cells[112] while 
CD44 has been identified as a reliable marker of mesenchymal cells[54]. Since our murine 
xenograft models of admix conditions were implanted in a 50/50 ratio, and I showed that 
epithelial and mesenchymal cells display no significant difference in proliferation rates in 
vitro (Figure 2B,C) I hypothesized both epithelial and mesenchymal cells would continue 
to maintain a 50/50 ratio within admix xenografts. To test this hypothesis, I performed IHC 
staining for E-Cadherin and CD44 on frozen sections prepared from the xenograft tumors. 
I found high levels of E-Cadherin expression in epithelial HCC827 tumors and high levels 
of CD44 in mesenchymal ER23 tumors. I found more cells with E-Cadherin expression 
than cells with CD44 expression in the admix tumors. The CD44-positive mesenchymal 




















Figure 3. HCC827/ER23 50/50 Admix at Time of Implantation Results in an Epithelial Dominated Tumor at 24 Days 
Representative images from murine sub-cutaneous xenografts established by epithelial HCC827 cells, mesenchymal ER23 cells or a 
50/50 admix stained for epithelial marker E-Cadherin or mesenchymal marker CD44. All micrographs are taken at 20x magnification. 
Scale bars represent 100µm. 







































The EMT Process Results in Differential Expression of Several Pro-Angiogenic and 
Growth Factors 
 
Since the increased tumorigenicity of epithelial and mesenchymal admix cells 
were observed only in vivo, I sought to determine if tumor-host interaction might be the 
causal factor for the observed growth advantage. I hypothesized that a change in gene 
expression during EMT may be establishing a signaling pathway between the tumor and 
host vasculature. To assess whether the EMT process results in a change in expression in 
factors known to influence blood vasculature, I performed a Luminex multiplex assay 
analyzing the concentrations of secreted factors by epithelial or mesenchymal cells into 
the media in an in vitro culture over a 48 hour growth period. I assessed the concentration 
of VEGF-A, EDN1, FGF-2, VEGF-C, VEGF-D, Angiopoietin-2, FGF-1, HGF, PLGF 
and endoglin. I compared epithelial HCC4006, HCC827, and HCC827 shNT to 
mesenchymal HCC4006Ge-R, ER23, HCC4006 O-R, and HCC827 shCDH1. I observed 
that all epithelial and mesenchymal cell lines tested secreted similar concentrations of 
VEGF-C, VEGF-D, FGF-1, HGF, PLGF, and endoglin. I discovered that VEGF-A 
secretion was lower in all mesenchymal cell lines tested compared to epithelial cells. 
Furthermore, I observed that EDN1 secretion was higher in all mesenchymal cell lines 
tested compared to epithelial cells (Figure 4). While Angiopoietin-2 was significantly up-
regulated in HCC827 when mesenchymal phenotype was induced, the same increase was 
not seen in HCC4006 with a mesenchymal phenotype. FGF-2 secretion was high in 
HCC4006Ge-R or HCC4006O-R compared to epithelial HCC4006 although this result 
was not observed in HCC827 cells (Figure 4). I therefore focused on the secreted 







Figure 4. EMT Process Results in Differential Expression of Several Pro-Angiogenic and 
Growth Factors. Luminex multiplex angiogenesis/growth factor multiplex assay analysis 
comparing HCC4006/HCC4006 Ge-R, HCC827/ER23, HCC4006/HCC4006 O-R, and HCC827 
shNT/HCC827 shCDH1. Cell culture supernatant was collected and analyzed for secreted 
concentrations of VEGF-A, VEGF-C, VEGF-D, EDN1, FGF-1, FGF-2, angiopoietin-2, HGF, 
PLGF and endoglin. All epithelial cell lines have been labeled with an E while all mesenchymal 







Induction of EMT or EGFR Inhibition Results in a Significant Increase in EDN1 
Secretion and Decrease in VEGF-A Secretion 
I evaluated our Luminex Multiplex assay results quantitatively using a one-way 
ANOVA analysis with a post hoc student's T test for significance. I found that in 
comparing HCC4006 and HCC4006Ge-R there was a significant reduction in VEGF-A 
secretion (p<0.001) coupled with a significant increase in EDN1 secretion (p<0.001) 
during a 48 hour growth period. Furthermore, I observed no significant reduction in 
VEGF-A secretion in a 50/50 epithelial/mesenchymal admix compared to epithelial alone 
coupled with a significant decrease in EDN1 concentration (Figure 5A). This may be due 
to EDN1 being secreted by mesenchymal HCC4006Ge-R cells and taken up by epithelial 
HCC4006 cells. I sought to replicate this result in other cell lines. I saw a significant 
increase in EDN1 secretion (p<0.001) coupled with a significant decrease in VEGF-A 
secretion (p<0.001) in mesenchymal HCC4006O-R compared to epithelial HCC4006 cells 
(Figure 5B). I also observed a significant increase in EDN1 secretion (p<0.001) coupled 
with a significant increase in EDN1 secretion (p<0.001) when comparing mesenchymal 
ER23 or HCC827 shCDH1 compared to epithelial HCC827 cells (Figure 5C,D). I also 
observed a non-significant reduction in VEGF-A secretion when HCC827 cells were 
grown in a 50/50 admix with ER23 cells while EDN1 expression was predictably found to 
be at ~%50 of that of a pure mesenchymal ER23 cell culture. Because EDN1 
concentrations were not depleted in our 50/50 admix condition, we used HCC827/ER23 
cell lines for all in vivo studies. It remained unclear whether this change from VEGF-A to 
EDN1 secretion represented an event in the EMT process or a consequence of EGFR 





72 hours. I observed that short-term gefitinib was sufficient to induce a significant up-










Figure 5: Induction of EMT or EGFR Inhibition Results in a Significant Increase in EDN1 Secretion and Decrease in VEGF-A 
Secretion. A) Epithelial HCC4006 showed robust levels of VEGF-A secretion and relatively low levels of EDN1 whereas 
mesenchymal HCC4006 Ge-R cells secreted significantly greater concentrations of EDN1 and significantly lower concentrations of 
VEGF-A (p<0.0001). No significant change in VEGF-A secretion was seen under 50/50 or 10/90 epithelial and mesenchymal co-
culture conditions. B) Epithelial HCC4006 and mesenchymal HCC4006 O-R cell lines exhibit a significant loss of VEGF-A secretion 
coupled with a significant gain in EDN1 secretion(p<0.0001). C) Epithelial HCC827 and mesenchymal ER23 cell lines exhibit a 
significant loss of VEGF-A secretion coupled with a significant gain in EDN1 secretion(p<0.0001). D) Epithelial HCC827 shNT and 
mesenchymal HCC827 shCDH1 cell lines exhibit a significant loss of VEGF-A secretion coupled with a significant gain in EDN1 
secretion(p<0.0001). E) 72 hour EGFR TKI treatment (100nM gefitinib) was sufficient to cause the loss of VEGF-A secretion and 






Epithelial/Mesenchymal Admix Conditioned Media Confers Greater Differentiation 
Potential in Cultured HUVEC Endothelial Cells Compared to Epithelial or 
Mesenchymal Pure Culture Conditioned Media 
It has been previously shown that in vitro tube formation is enhanced under both 
10nmol/L EDN1 and 1ng/ml VEGF-A when performed with HUVEC cells. These factors 
demonstrated a synergistic effect leading to greater angiogenic potential when used in 
combination compared to either agent alone[83]. Since I have already seen notable 
concentrations of VEGF-A and EDN1 in epithelial and mesenchymal cell culture 
supernatant respectively, I hypothesized that conditioned media produced from admix 
conditions would contain significant levels of both VEGF-A and EDN1. If true, admix 
conditioned media would offer greater angiogenic potential in a tube formation assay 
compared  to epithelial or mesenchymal cells grown alone. In an 8 hour tube formation 
assay, the condition media from HCC4006 and HCC4006Ge-R cells grown in a 50/50 
admix promoted greater tube formation potential compared to supernatants from HCC4006 
or HCC4006Ge-R cells (Figure 6A). Images were captured with an Evos FL Cell Imaging 
System (AMD, AMF4300) in the GFP channel. Images were analyzed using the ImageJ 
Angiogenesis Analyzer plugin provided as free software from the Gilles Carpentier 
Research Group[107]. A significant increase in the number of nodes (p<0.01), total tubule 
length (p<0.01) and mesh area (p<0.001) was seen in HCC4006 and Ge-R cells grown in a 
50/50 admix when compared to negative control EBM or HCC4006 or Ge-R cells grown in 









Figure 6. Epithelial/Mesenchymal Admix Conditioned Media Confers Greater Differentiation Potential in Cultured 
HUVEC Cells Compared to Epithelial or Mesenchymal Pure Culture Conditions. A) Qualitative comparison of conditioned 
media produced from epithelial HCC4006 cells, mesenchymal HCC4006 Ge-R cells, and HCC4006/HCC4006 Ge-R cells grown 
in 50/50 admix. Tube formation in basal media (EMB) and fully supplemented growth media (EGM-2) has been included as 
negative and positive controls respectively. Images are representative of 3 repeat experiments. Traces in green represent total tube 
length; red points represent nodes, blue traces represent mesh areas. B) ImageJ angiogenesis quantification of commonly analyzed 
tube formation parameters including mesh area (p<0.001), total tubule length (p<0.01) and number of nodes (p<0.01). 






To test if the result that increased tube formation in supernatant from the admix cells 
is due primarily to the presence of VEGF-A and EDN1, I performed a tube formation assay 
in growth factor reduced EBM with either 10nM VEGF-A, 10nM EDN1 or a combination of 
10nM VEGF-A and 10nM EDN1 (Figure 7A). These concentrations were calculated from 
the concentrations of VEGF-A and EDN1 as measured by Luminex analysis (Figure 5). I 
found that while all conditions failed to produce a significant increase in tube formation 
above basal levels, a clear trend toward enhanced tube formation was present in the 












Figure 7. In Vitro Angiogenesis Analyzed by Tube Formation Assay. A) Qualitative comparison of tube formation in basal 
EBM media supplemented with 10ng/mL VEGF-A, 10nM EDN1 or a combination of both factors. Tube formation in basal media 
EMB and fully supplemented EGM-2 has been included as negative and positive controls respectively. Images are representative 
of 3 repeat experiments. B) ImageJ angiogenesis quantification of commonly analyzed tube formation parameters including, total 
tubule length and number of nodes. Significance determined by one-way ANOVA with post hoc student's t-test. Error bars 





Sunitinib/Zibotentan Combination Therapy Effectively Inhibits Tube Formation In 
Vitro 
 
To further test if the increased tube formation in the conditioned media from the 
admix cells are due to the effects of VEGF-A and END1, I utilized chemical inhibitors of 
VEGFR2 and EDNRA, sunitinib and Zibotentan respectively, to investigate if inhibition of 
VEGFR2 and EDNRA could suppress tube formation by the condition media. While 
sunitinib is known to also inhibit PDGFRs and other VEGFRs, its main target is VEGFR2. 
Zibotentan was chosen because it is a specific inhibitor to EDNRA. Representative images 
from tube formation in untreated admix conditions, low-dose 10nM sunitinib treatment, 
low-dose 100nM Zibotentan treatment, and dual drug treatment were obtained (Figure 
8A). Upon quantification, I observed that low dose (10nM) sunitinib did not produce a 
significant reduction in tube formation in conditioned media produced from admix 
conditions. Likewise, low dose (100nM) Zibotentan did not produce a significant reduction 
in tube formation in conditioned media produced from admix conditions. The combination 
of 10nM sunitinib and 100nM Zibotentan significantly inhibited tube formation (p<0.01) 
in admix conditioned media (Figure 8B). I therefore showed that the combination 












Figure 8. In Vitro Inhibition of Angiogenesis Analyzed by Tube Formation Assay. A) Qualitative comparison of tube 
formation in conditioned media produced from a 50/50 admix of epithelial HCC4006 and mesenchymal GER cells treated with 
10nM Sunitinib, 100nM Zibotentan, or a combination of the two factors, respectively. Images are representative of 3 repeat 
experiments. B) ImageJ angiogenesis quantification of commonly analyzed tube formation parameters including number of nodes, 
total tubule length and total mesh area. Significance determined by one-way ANOVA with post hoc student's t-test. Error bars 





The Expression of EDNRA and Phosphorylated VEGFR2 in HUVEC Cells is Increased 
Under 8H Stimulation by Admix Conditioned Media and Sunitinib Abrogates VEGFR 
Phosphorylation 
Since VEGF-A has been shown to primarily exhibit its pro-angiogenic effect 
through the VEGFR2 receptor, I consider VEGFR2 phosphorylation as a marker of VEGF-
A activity[91]. While VEGF-A has been shown to strongly bind to VEGFR1, the receptor 
has been shown to have a weak effect on angiogenesis[113]. I therefore focused our studies 
on VEGFR2 signaling. To test whether I am effectively inhibiting VEGFR2 through low 
dose 10nM sunitinib treatment, I examined VEGFR2 signaling under stimulation by 
conditioned media produced from epithelial HCC4006 cells and mesenchymal 
HCC4006GE-R cells grown under 50/50 admix conditions (Figure 9). I found that while 
total VEGFR2 was comparable under all conditions tested, phosphorylated VEGFR2 was 
up-regulated under stimulation by conditioned media produced under admix conditions or 
by complete EGM which contains no VEGF-A or EDN1. Phosphorylated VEGFR2 was 
abrogated by low dose 10nM sunitinib treatment when added to either admix conditioned 
media or complete EGM. I observed that EDNRA levels are decreased under unstimulated 
8h EBM conditions while EDNRA levels are comparable when stimulated by conditioned 
media or complete EGM in the presence or absence of sunitinib treatment (Figure 9). 












Figure 9. HUVEC Cells Express EDNRA and Phosphorylated VEGFR2 is Up-
Regulated Under 8H Stimulation by Admix Conditioned Media While Being Effectively 
Abrogated by 10nM Sunitinib Treatment. Western blot comparing expression of EDNRA, 
VEGFR2, and pVEGFR2 under unstimulated conditions (8H basal EBM media) or 








NSCLC Cells Lines with an EDN1 Over-Expression or Knock-Down Phenotype 
maintain VEGF-A Secretion In Vitro and EDN1 Secretion was Associated With 
Significantly Lower Tumor Growth 
I sought to analyze the effect of EDN1 on the tumor microenvironment in vivo, 
therefore, I generated a HCC827 cell line which ectopically expresses EDN1 using a pLX 
lentiviral expression vector (HCC827 EDN1). I used HCC827 cells transduced with a pLX 
vector lentivirus coding for flag-V5 as a control (HCC827 Flag/V5). Upon antibiotic 
marker selection, I ensured constitutive EDN1 secretion in the supernatant from HCC827 
pLX EDN1 cells using Luminex assay. Additionally, the secretion of VEGF-A was 
maintained in these cells (Figure 10A). Interestingly, when I performed a sub-cutaneous 
xenograft experiment comparing the growth of HCC827 Flag/V5 to HCC827 EDN1, I 
observed that HCC827 Flag/V5 cells showed a growth advantage compared to HCC827 
EDN1 as analyzed by caliper measurement (Figure 10B). To test if secretory EDN1 
attenuates in vivo tumor growth, I generated HCC4006Ge-R cells with either an EDN1 or 
non-target knockdown. The depletion of EDN1was confirmed in supernatants from the 
engineered cells using the Luminex assay (Figure 10C). Interestingly, EDN1 knockdown in 
Ge-R cells resulted in a significant increase in VEGF-A secretion compared to non-target 
knockdown (Figure 10C). To further test the role of EDN1 on tumor growth rate, tumors 
grown with Ge-R shEDN1 in admix with epithelial HCC4006 cells were shown to possess 
a growth advantage in vivo compared to Ge-R shNT cells in admix with epithelial 
HCC4006 cells (Figure 10D). Taken together, these data suggest that EDN1 is not 










Figure 10: NSCLC Cells Lines Harboring EGFR Kinase Domain Mutations Maintain VEGF-A Secretion In Vitro When 
EDN1 is Either Over-Expressed or Knocked Down and Result in a Slower or Faster Growing Tumor Respectively In Vivo. 
All Error Bars Represent Standard Error of Mean Between Repeat Conditions. A) VEGF-A (ns) and EDN1 (p<0.001) 
secretion as measured by a Luminex multiplex assay analyzing conditioned media produced over 48h in HCC827 Flag/V5 or pLX 
EDN1. B) HCC827 pLX EDN1 significantly inhibits tumor growth compared to HCC827 pLX Flag/V5 tumors (p=0.0069). 
C) VEGF-A (p<0.01) and EDN1 (p<0.001) secretion as measured by a Luminex multiplex assay analyzing conditioned media 
produced over 48h in Ge-R shNT or Ge-R shEDN1. D) Ge-R shEDN1 grown in admix with HCC4006 significantly potentiates 





EDN1 Expressing Tumors Show Significantly Greater EGFR TKI Resistance In Vivo 
 
I observed that EDN1 expression did not correlate with a growth advantage in vivo, 
although it is known that EDN1 expression is a known negative prognostic marker in 
NSCLC. I therefore sought to test whether EDN1 expression could positively affect EGFR 
TKI resistance. I tested gefitinib sensitivity in epithelial HCC827 and gefitinib resistance in 
mesenchymal ER23 cells in vitro by MTS assay (Figure 11A). I subjected HCC827, ER23, 
and the admix xenograft tumors to a 6-day course of gefitinib (50mg/kg daily) treatment. 
Tumor volume was calculated using external caliper measurement and upon completion of 
the drug treatment, tumor volume was measured via caliper following tumor excision. 
Percent residual tumor was calculated by comparing tumor volume before and after the 
gefitinib treatment. I found that both pure mesenchymal and admix tumors show 
significantly higher residual tumor volume following gefitinib treatment compared to 
epithelial tumors (p<0.0001) (Figure 11B). I also treated HCC827 Flag/V5 and HCC827 
pLX EDN1 tumors with gefitinib for 6 days and measured tumor volume after excision 
from the mouse. I found that while EDN1 over-expression resulted in a slower growing 
tumor (Figure 10B), the resulting tumor was more resistant to gefitinib treatment as shown 
by a significantly greater residual tumor volume (p=0.0353) after 6 days of gefitinib 
treatment (Figure 11D). Taken together, these data suggest that EDN1 expression 









Figure 11. Mesenchymal or Epithelial/Mesenchymal Admix Tumors and Tumors Overexpressing EDN1 Result in 
Significantly Greater EGFR TKI Resistance In Vivo. Error Bars Represent Standard Error Between Means for All 
Figures. A) Sensitivity to gefitinib treatment as measured by MTS assay comparing HCC827 to ER23. B) Subcutaneous xenograft 
of mesenchymal ER23 and 50/50 admix of HCC827 and ER23 demonstrates significant drug resistance in vivo compared to pure 
epithelial xenografts (p<0.0001). C) Sensitivity to gefitinib treatment as measured by MTS assay comparing HCC827 pLX 






The Presence of EDN1 Secreting Cells in Admix Tumors or an Over-Expression Model 
Promotes Significantly Reduced Microvessel Density 
Because I observed significant drug resistance in tumors with an EDN1 secreting 
mesenchymal sub-population in vivo but not in vitro, I performed a literature search to 
identify tumor-host interactions involving EDN1 contributing to drug resistance. It has 
been previously shown that a lower MVD correlates with drug resistance in NSCLC[125]. 
I hypothesized that epithelial/mesenchymal admix conditions and mesenchymal xenografts 
would result in a tumor with lower MVD compared to epithelial tumors due to the 
vasoconstrictive properties of EDN1. By constricting local vessels, EDN1 may be limiting 
nutrient availability to the epithelial sub-population of the tumor. This effect would lower 
available VEGF-A secretion by epithelial cells and lead to lower MVD. Upon drug 
treatment, a diminished MVD may be leading to poor drug perfusion and an increase in 
apparent drug resistance in vivo. To explore this, I performed sub-cutaneous xenografts 
using epithelial HCC827, mesenchymal ER23 or a 50/50 admix. I prepared frozen sections 
from the resulting tumors and performed IHC staining for CD31. I chose to use CD31 as a 
marker for endothelial cells because it has been shown to be the best marker for blood 
vasculature in benign and malignant tumors[111]. Since CD31 is also expressed on 
platelets, macrophages, neutrophils and monocytes, I exclude any single cells staining 
positive for CD31. I considered any CD31+ cell cluster, clearly separated from adjacent 
microvessels, tumor tissue, or other tissue elements as a single countable microvessel[108]. 
I found a significant decrease in MVD in mesenchymal ER23 or HCC827/ER23 50/50 
admix tumors compared to epithelial HCC827 tumors (p<0.0001) (Figure 12A). I then 





performed sub-cutaneous xenografts using epithelial HCC4006 cells grown alone or in a 
50/50 admix with mesenchymal Ge-R cells with either an EDN1 knockdown or a non-
target knockdown (Figure 12B). Tumors produced from HCC4006 cells grown in admix 
with EDN1 secreting HCC4006Ge-R shNT cells (Figure 10C) show a significant decrease 
in MVD compared to HCC4006 (p<0.001). This effect was abrogated by lentiviral shRNA 
knockdown of EDN1 (Figure 12B). It is important to note that most areas of high vessel 
density were identified around the edges of the tumor section. This is most likely due to the 
short growth time of these tumors relative to their analog within a patient. Blood 
vasculature growth typically begins at the margins of a tumor and proceeds inward[124]. If 
a longer growth time was permissible, I would expect areas of high blood vessel density to 









Figure 12. Epithelial/Mesenchymal Admix Conditions Results in Significantly Lower Blood Vessel Density Which Can be 
Abrogated Through Knockdown of EDN1 in Mesenchymal Cells. Significance was Determined by One-Way ANOVA With 
a Post Hoc Student’s T-Test. Scale Bars Represent 100µm. Error Bars Represent Standard Error Between Means. 
A) Representative images from tumors produced from epithelial HCC827, and mesenchymal ER23 cells grown alone or in a 
50/50. Images taken at 20x magnification. MVD was calculated by the “hot spot” method as previously described. B) 
Representative images from tumors produced from epithelial HCC4006, and HCC4006 cells grown in admix with mesenchymal 
Ge-R cells with a non-target or EDN1 shRNA knockdown. Images taken at 20x magnification. MVD was calculated by the “hot 





Phosphorylated EGFR is Maintained in Gefitinib Treated Mesenchymal and Admix 
Tumors 
 
Phosphorylated EGFR has been accepted as a reliable pharmacodynamics marker 
for EGFR TKIs. Consequently, I could assess the bioavailability of EGFR TKIs in the 
tumor by measuring the level of pEGFR[114]. I found that epithelial/mesenchymal admix 
xenograft tumors are significantly more resistant to EGFR TKIs than epithelial xenograft 
tumors (Figure 11B). I first wanted to assess if EGFR TKIs were effectively delivered to 
admix xenografts by measuring p-EGFR by IHC staining. To produce representative 
images, 2 tumors from untreated conditions and 4 tumors from treated conditions were 
examined. I performed IHC staining for phosphorylated EGFR on tumor sections prepared 
from epithelial HCC827, mesenchymal ER23 or admix tumors. I found that phosphorylated 
EGFR was effectively reduced by gefitinib treatment in epithelial HCC827 tumors while 
phosphorylated EGFR was maintained in mesenchymal ER23 and admix tumors (Figure 
13). I also examined total EGFR expression by IHC staining in the same set of samples. I 
found that total EGFR expression was comparable across all untreated conditions. Among 
gefitinib treated tumors, epithelial HCC827 tumors show a disruption of solid structure and 
a down-regulation of EGFR while mesenchymal ER23 tumors and admix tumors display a 
maintenance of total EGFR expression (Figure 14). The disruption of a densely packed 
tumor cell structure and the adoption of a spongiform morphology has been associated 












Figure 13. Phosphorylated EGFR is Maintained in Gefitinib Treated Mesenchymal and Admix Conditions. Representative 
images from murine sub-cutaneous xenografts established by epithelial HCC827 cells, mesenchymal ER23 cells or a 50/50 admix 



















Figure 14: Total EGFR is Comparable in Untreated Conditions While Total EGFR is Maintained in Gefitinib Treated 
Mesenchymal ER23 and Admix Tumors. Representative images from murine sub-cutaneous xenografts established by epithelial 
HCC827 cells, mesenchymal ER23 cells or a 50/50 admix stained for total EGFR. All micrographs are taken at 20x magnification. 








Activating EGFR mutations in NSCLC patients allow for the use of therapies 
targeting EGFR signaling. While EGFR TKI therapy is initially efficacious in most EGFR 
mutation positive NSCLC patients, the disease eventually progresses after the emergence 
of acquired resistance and limits the efficacy of this therapy[25]. In an attempt to 
circumvent the limitations of EGFR TKI therapy, several clinical trials were performed 
attempting to limit the effect of tumor neo-angiogenesis in NSCLC. These trials focused on 
the inhibition of VEGFR2 signaling to prevent neo-angiogenesis, a prerequisite for the 
tumor colonization upon metastasis. Unfortunately, the treatment combining VEGFR2 
inhibitors with standard chemotherapy or EGFR TKIs show little to no survival advantage 
over therapeutic regimens which do not include VEGFR2 inhibition[93, 103-105]. This 
result is surprising due to the documented importance of tumor neo-angiogenesis in tumor 
growth and disease progression as well as the documented VEGFR2 expression in NSCLC 
tumors. Since patients showing resistance to EGFR TKI therapy also commonly present a 
heterogeneous tumor, I sought to explore whether tumor heterogeneity could explain why 
VEGFR2-based therapies failed in the clinic. In order to study this question, we must 
understand the dynamics of how tumor heterogeneity emerges in the patient. 





cell[115]. While there has since been evidence to support this model[116], limitations in 
tumor biopsy sampling protocols do not allow for the exclusion of a multicellular origin in 
some human tumor types. Regardless of mechanism of origin, it is generally accepted that 
tumor heterogeneity increases over time and in response to drug treatment in human 
patients. Indeed, at time of diagnosis, the majority of tumors display heterogeneity in 
regards to several morphological and physiological characteristics. These differential 
characteristics often manifest in cell surface receptor expression, proliferative capacity and 
angiogenic potential.  
The induction of an EMT phenotype has been studied in at least two major ways. 
The first involves exposing epithelial cells to increasing concentrations of EGFR TKIs over 
a period of time[55]. The second involves the depletion of epithelial markers such as E-
Cadherin by lentiviral shRNA transduction[117]. The advantage of studying EGFR TKI 
resistance by EMT in cells chronically exposed to increasing doses of EGFR TKIs is that it 
represents the direct in vitro analog of the EMT phenotype which emerges in patients 
undergoing EGFR TKI therapy. However, off- target effects of drug treatment may result in 
changes in expression independent of the EMT process. Induction of EMT by lentiviral 
shRNA knockdown of E-Cadherin eliminates the possibility of EMT- independent changes 
in expression, however the mechanism of induction is artificial and not seen in patients. It 
is therefore imperative to study EMT mediated EGFR TKI resistance by using a multitude 
of cell lines created through both processes. In order to study EMT-mediated EGFR TKI 
resistance in NSCLC cells, I utilized cells with a mesenchymal phenotype produced from 
chronic exposure to EGFR TKI treatment or through lentiviral knockdown of the epithelial 





for the generation of NSCLC cell lines displaying a mesenchymal phenotype. The 
mesenchymal properties of these cell lines form the basis of our study on EMT-mediated 
tumor heterogeneity. 
I initially set out to determine how epithelial and mesenchymal lung cancer cells 
interact in vivo. To this end, I performed a sub-cutaneous xenograft in a murine model with 
epithelial HCC827, mesenchymal ER23 cells, or a 50/50 admix. I found that admix 
conditions produce tumors with greater volume compared to either epithelial or 
mesenchymal cells alone. In order to determine if this effect was due to signaling between 
epithelial and mesenchymal cells, I performed an in vitro growth assay using epithelial 
cells, mesenchymal cells or multiple admix conditions and measured cell count over a 6 
day period. I found that while admix conditions produced a growth advantage in vivo 
(Figure 2A), this effect was not present in vitro (Figure 2B,C). If an interaction between 
epithelial cells and mesenchymal cells could explain the growth advantage seen under 
admix conditions in vivo I would expect this result to be replicated in vitro. Since I did not 
see this, it suggests that the growth advantage seen in vivo may be due to tumor-host 
microenvironment interaction. 
One major way in which tumors are known to interact with the host is through the 
blood vasculature. During excision of our xenograft tumors, it was observed that admix 
tumors seemed to have greater blood vasculature compared to epithelial or mesenchymal. I 
hypothesized that the interaction between admix tumors and the host vasculature may 
explain why admix conditions confer a growth advantage in vivo but not in vitro. To 
determine if EMT affected the expression of angiogenesis-related growth factors, I 





By performing this assay on supernatants from epithelial, mesenchymal or admix cell 
culture, I can measure the amount of each secreted factor. I focused on the effect of EMT 
on the secretion of VEGF-A and EDN1 since these showed differential secretion in all cell 
lines tested when comparing epithelial to mesenchymal cells. I found that during the EMT 
process, the secretion of VEGF-A was significantly reduced while the secretion of EDN1 
was significantly up-regulated (Figure 5A-D). Interestingly, in 50/50 
HCC4006/HCC4006Ge-R admix conditions I found that VEGF-A secretion was 
comparable to that of epithelial HCC4006 alone. While I expected to see an approximately 
50% reduction in EDN1 secretion due to half of the number of mesenchymal HCC4006Ge-
R cells seeded in the 50/50 admix compared to HCC4006Ge-R pure culture, I found a 
significantly lower EDN1 concentration in the 50/50 admix. It is possible that in HCC4006 
cell lines, EDN1 secreted by mesenchymal cells is taken up by epithelial cells leading to 
increased VEGF-A secretion. This result was not replicated in a comparison between 
epithelial HCC827 and mesenchymal ER23 cell lines. In these cell lines, a 50/50 admix 
produced VEGF-A concentrations similar to epithelial cells alone and EDN1 
concentrations approximately 50% of that of mesenchymal cells alone. Based on this result 
we used HCC827 and ER23 cell lines for our admix in vivo studies. 
It was unclear whether this change in secretion was an early or late event in the 
EMT process, therefore I measured factors secreted by epithelial HCC4006 cells treated 
with short-term (72 hours) 100nM gefitinib treatment. I found that 72 hours of gefitinib 
treatment was sufficient to produce the switch from primarily VEGF-A secretion to 
primarily EDN1 secretion (Figure 5E). I therefore conclude that the switch from VEGF-A 





consequence of EGFR inhibition. These events may be linked considering short-term 
EGFR inhibition has been shown to induce TGF-β expression which can result in 
EMT[55]. I believe that EGFR TKI treatment primes the cell for the switch from VEGF-A 
secretion to EDN1 secretion during the EMT process. This change in expression may result 
in greater tumor neo-angiogenesis providing a possible explanation of why admix tumors 
show a growth advantage in vivo. 
Using in vitro tube formation assay, I determined the effect of VEGF-A and EDN1 
on endothelial cell differentiation. By depositing endothelial HUVEC cells onto a reduced-
growth factor Matrigel coated plate, I exposed endothelial cells to conditioned media 
produced from epithelial, mesenchymal or admix cell cultures. By measuring the formation 
of tube structures I can measure the ability of conditioned media to induce differentiation in 
endothelial cells. I found that conditioned media produced from admix culture conditions 
induced greater tube structure compared to epithelial or mesenchymal cells alone (Figure 
6A). By utilizing the ImageJ angiogenesis analyzer plugin[107], I objectively quantified 
several parameters useful for assessing the differentiation of endothelial cells. I focus on 
total tubule length, node count, and mesh area. The total tubule length measurement is an 
indicator of overall differentiation level. The node count parameter is analogous to the 
sprouting step of in vivo angiogenesis in which endothelial cells differentiate to establish an 
outgrowth from an established blood vessel. Mesh area is analogous to the ability for newly 
established blood vessels to join with already established blood vessel structures in vivo and 
therefore represents the highest-order organization of blood vasculature structure. I found 
that conditioned media from admix culture conditions showed a significant increase in total 





induces greater endothelial cell differentiation compared to epithelial or mesenchymal pure 
culture conditions in vitro (Figure 6B). 
To test if the presence of both VEGF-A and EDN1 could explain the increased 
endothelial cell differentiation seen in our conditioned media experiment in vitro, I 
performed the tube formation assay using exogenous recombinant VEGF-A and EDN1 
(Figure 7A). I found that the addition of both of these factors was sufficient to produce a 
trend toward a greater tube formation morphology compared to either factor alone or basal 
media conditions. Our ImageJ quantification of this experiment lacks mesh area due to the 
overall lower tube formation compared to the conditioned media experiment. The addition 
of both factors did not produce a significant increase in total tube length and node count 
although a clear trend is present (Figure 7B). I rationalize this by acknowledging the diverse 
population of unknown growth factors that may be present in conditioned media. While 
VEGF- A and EDN1 secretion is an important component to this population, it likely does 
not represent the only EMT-mediated change in growth factor secretion important in blood 
vasculature regulation. Indeed I observed an up-regulation of several other angiogenesis-
related growth factors in our cell lines such as FGF-2 or angiopoietin-2 upon the EMT 
process (Figure 4). While these factors were only shown be up-regulated in HCC4006 and 
HCC827 cell lines respectively, it is possible these factors individually contribute to 
endothelial cell differentiation. Additionally, I recognize that our conditioned media 
preparation is somewhat of a black box in which unmeasured factors may be contributing to 
VEGF-A/EDN1-mediated endothelial cell differentiation. 
I then sought to test whether the VEGF-A/EDN1 signaling systems were targetable 





utilized the VEGFR2 inhibitor sunitinib and the EDNRA specific inhibitor Zibotentan. 
Sunitinib is a potent multi- target inhibitor sold under the trade name Sutent by Pfizer Inc. 
It was first approved for use in renal cell carcinoma and imatinib-resistant gastrointestinal 
stromal tumors on January 26, 2006. Sunitinib is able to inhibit all receptors for platelet-
derived growth factor and all VEGF species receptors. Sunitinib has also been shown to 
inhibit the receptor tyrosine kinase CD117 (c-KIT)[105]. Zibotentan is an EDNRA specific 
inhibitor developed by AstraZeneca for use in the treatment of prostate cancer. The drug 
failed a phase III clinical trial for prostate cancer and has since been discontinued after 
failing to show any survival benefit to patients[118]. I chose to use Zibotentan due to its 
EDNRA- specific activity and the efficacy of the drug for inhibiting EDNRA signaling in 
vitro. Because a sufficiently high concentration of either of these drugs can effectively 
inhibit tube formation by conditioned media, I must establish low-dose concentrations of 
each drug in order to examine the benefit of dual therapy. I found that 10nM sunitinib and 
100nM Zibotentan failed to significantly inhibit tube formation induced by admix cell 
culture conditioned media when used alone. In contrast, the combination treatment at these 
concentrations significantly abrogated tube formation as measured by ImageJ 
quantification of node count, total tubule length and mesh area (Figure 8). These results 
suggest that the dual treatment of sunitinib/Zibotentan sufficient to abrogate the additive 
effect these growth factors have on endothelial cell differentiation. In order to test if our 
low dose 10nM sunitinib treatment was effectively able to abrogate VEGF-A mediated 
signaling, I examined the effect of stimulation by conditioned media produced from admix 
culture conditions on HUVEC cells. I exposed HUVEC cells to admix conditioned media 





admix conditioned media effectively up-regulated phosphorylated VEGFR2 as expected. 
Furthermore, the addition of 10nM sunitinib was sufficient to down-regulate 
phosphorylated VEGFR in admix conditioned media or EGM conditions. These results 
suggest 10nM sunitinib is an effective concentration for the inhibition of VEGFR2 in 
HUVEC cells (Figure 9). This result supports our dual VEGFR2/EDNRA inhibition tube 
formation assay. Since I am able to effectively reduce phosphorylated VEGFR2 by 10nM 
sunitinib treatment, tube formation seen under single target sunitinib treatment must be due 
to other growth factors present in admix conditioned media; possibly EDN1. This result 
highlights the importance of multiple signaling pathways in the induction of a tube 
formation morphology in vitro. I also examined EDNRA expression and found that 
EDNRA is down-regulated after 8 hours in basal EBM media unstimulated conditions. 
EDNRA expression was seen to be comparable among stimulated conditions with or 
without sunitinib treatment. Since EDNRA activation opens the L-type Ca2+ channel 
resulting in the influx of Ca2+ to the cytosol, the quantification of intracellular Ca2+ 
concentration using flow cytometry is commonly accepted as an assay to assess EDNRA 
activation by the EDN1 stimulation[119]. In order to exclude other Ca2+ channel activators 
present in conditioned media, I will need to perform the assay to evaluate if recombinant 
EDN1 would activate EDNRA in vascular endothelial cells and if the activation can be 
abrogated by 100nM Zibotentan treatment. 
In order to study the specific effects of EDN1 in the tumor microenvironment in 
vivo, I produced epithelial HCC827 cell lines ectopically expressing EDN1 or Flag/V5 
control. I confirmed VEGF-A secretion was maintained by Luminex analysis (Figure 





significant growth retardation compared to HCC827 Flag/V5 cells (Figure 10B). This 
result forced us to reconsider the effect of EDN1 in the tumor microenvironment. I have 
shown that EDN1 secretion is up-regulated in cells with a mesenchymal phenotype, and it 
is well known that tumors harboring a mesenchymal sub-population are significantly more 
resistant to EGFR TKI treatment[57]. I therefore hypothesized that EDN1 secretion in the 
tumor microenvironment may be contributing to drug resistance. While EDN1 secretion 
has been linked to increased MVD in several tumor types including ovarian carcinoma[69] 
and chondrosarcoma[84], the opposite has been found in castration-resistant prostate 
cancer[85] and some melanomas[86]. The decreased tumor growth in these cancers were 
attributed to the vasoconstrictive properties of EDN1 preventing sufficient blood flow to 
the tumor. If this is also true in a NSCLC model, it would explain why EDN1 over-
expressing tumors show significant growth retardation. Upon drug treatment, the 
decreased MVD would become beneficial to the tumor by limiting drug perfusion within 
the tumor. I hypothesized that the vasconstrictive property of EDN1 was contributing to 
EGFR TKI resistance in our NSCLC model. 
Therefore, I returned to our epithelial HCC827, mesenchymal ER23 and admix 
condition xenograft model. Upon 6-day gefitinib treatment, I observed significantly greater 
residual tumor volume in admix and mesenchymal tumors compared to epithelial (Figure 
11B). I hypothesize that EDN1 is limiting blood supply to the tumor therefore limiting the 
growth of the epithelial component of admix tumors. Since epithelial cells are the main 
contributor to VEGF-A secretion, EDN1 could exert an anti-angiogenic effect on admix 
tumors. Additionally, upon EGFR TKI treatment, epithelial cells switch from VEGF-A 





the presence of constitutively EDN1 secreting mesenchymal cells may prime the tumor to 
competently constrict the relevant vasculature to prevent drug perfusion. 
To test if EGFR TKI resistance was due to EDN1 secretion, I subjected our 
HCC827 EDN1 over-expression xenografts to a 6-day gefitinib treatment and measured 
residual tumor volume by caliper measurement. HCC827 EDN1 expressing tumors were 
allowed to reach the same volume as Flag/V5 control prior to treatment. I found that 
HCC827 EDN1 over-expressing tumors showed significantly greater residual tumor 
volume compared to HCC827 Flag/V5 following gefitinib treatment (Figure 11D). As 
expected, EDN1 over-expressing cells showed no significant increase in gefitinib 
resistance in vitro (Figure 11C). This further implicated the host vasculature in EDN1- 
mediated EGFR TKI resistance. If EDN1 was acting to decrease MVD in our NSCLC 
model, I would expect a lower MVD in admix tumors. Indeed I observed that MVD was 
significantly reduced in admix and mesenchymal tumors compared to epithelial (Figure 
12A). In order to determine if this effect was due to EDN1 secretion, I established 
mesenchymal HCC4006Ge-R cell lines expressing a shRNA knockdown of EDN1 or non-
target control. A murine xenograft was performed and CD31 staining was conducted on 
the resulting tumors. I found that EDN1-competent HCC4006Ge-R shNT cells grown in 
admix with epithelial HCC4006 cells show significantly lower blood vessel density 
compared to HCC4006 alone. This effect can be abrogated through the knockdown of 
EDN1 in mesenchymal HCC4006Ge-R cells grown in admix with HCC4006 cells (Figure 
12B). This result further supports the hypothesis that EDN1 secretion within the tumor 
microenvironment is contributing to MVD depression. If this were true, I would expect 





To indirectly assess the penetrance of EGFR TKIs in epithelial, mesenchymal and 
admix tumors, I measured total EGFR expression as well as the phosphorylation of EGFR 
in these tumors by IHC staining. I found that EGFR is expressed at comparable levels in 
untreated epithelial, mesenchymal or admix tumors. Epithelial tumors treated with gefitinib 
showed wide-scale destruction of tumor structure as well as a down regulation of EGFR 
expression. Conversely, mesenchymal and admix tumors showed a maintenance of EGFR 
expression upon gefitinib treatment (Figure 14). The phosphorylation of EGFR serves as a 
pharmacodynamics marker of EGFR activity and the effectiveness of inhibition by EGFR 
TKIs[114]. Therefore, I performed IHC staining for phosphorylated EGFR in untreated and 
treated epithelial, mesenchymal or admix tumors to indirectly assess the penetrance of 
EGFR TKIs in the tumors. I observed that gefitinib treatment abrogated the phosphorylated 
EGFR signal in epithelial tumors suggesting the availability of gefitinib was sufficient to 
inhibit EGFR activity. Interestingly, both mesenchymal and admix tumors maintained 
phosphorylated EGFR following gefitinib treatment (Figure 13). Since both mesenchymal 
and epithelial cells harbor mutated EGFR that is constitutively active and exquisitely 
sensitive to EGFR TKIs, an insufficient amount of EGFR inhibitor may available in these 
tumors to fully suppress the EGFR phosphorylation. Surprisingly, I found that admix 
tumors are epithelial phenotype dominated (Figure 3). Since tumors grown from epithelial 
cells alone show exquisite sensitivity to EGFR TKIs, I conclude that the drug is not 
thoroughly penetrating these tumors. In order to test if poor EGFR TKI penetrance in the 
tumors is caused by the presence of EDN1, tumor samples need to be tested for 
intratumoral gefitinib concentration using mass spectrometry. To this end I have sent tumor 





significantly decreased concentration of gefitinib in mesenchymal and admix conditions 
compared to epithelial as well as decreased gefitinib concentrations in EDN1 over-
expressing tumors compared to Flag/V5 controls. I exclude the possibility of gefitinib-
mediated EMT in drug treated tumors due to the short time period in which the drug 
treatment took place. In the clinic, EMT normally arises from EGFR TKI treatment over a 
period of ~6 months. Since our drug treatment period was limited to 6 days, this excludes 
the possibility that drug resistance could be explainable by gefitinib-mediated EMT. 
I believe the growth advantage of admix conditions to not be explainable by the 
presence of EDN1 secreting cells within admix conditions. Indeed, tumors grown from 
HCC827 EDN1 over- expressing cells showed a significant growth retardation compared 
to HCC827 Flag/V5 cells (Figure 10B). I believe I did not capture the growth advantage of 
admix conditions in vitro because of the normoxic conditions used. Factors secreted by 
mesenchymal cells may show differential effects in the relatively hypoxic conditions 
present in vivo. Marek et al. described an autocrine feedback loop between epithelial and 
mesenchymal NSCLC cell lines involving the FGF-2 signaling pathway[120]. I also 
observed an up-regulation of FGF-2 in our mesenchymal HCC4006Ge-R cells compared 
to epithelial HCC4006 cells (Figure 4). Additionally, FGF-2 expression is well known to 
be up-regulated under hypoxic conditions[121]. I speculate that under hypoxic conditions, 
I may have observed a growth advantage in vitro in admix conditions compared to 
epithelial or mesenchymal pure cultures. 
The in vitro tube formation assay inherently excludes the effect of vasoconstriction 
due to the lack of the smooth muscle that normally sheaths mature blood vessels in vivo. 





endothelial cells. In light of this realization, it makes sense that our in vitro results did not 
support our in vivo results. If only considering our in vitro results, I would propose that 
EDNRA inhibition may be an important addition to VEGFR2 inhibition-based treatment 
regimens due to the pro-angiogenic nature of EDN1 contributing to increased MVD in the 
tumor. Given that VEGFR2 inhibition in NSCLC clinical trials has been largely 
ineffective, I would pose that the switch between VEGF-A secretion to EDN1 secretion 
during EMT or EGFR TKI treatment (Figure 5A-E) represents an escape mechanism to 
VEGFR2 inhibition. In light of our in vivo results, I recommend EDNRA inhibition as an 
effective addition to a blood vascular-based approach to NSCLC treatment not to inhibit 
angiogenesis but to increase MVD leading to increased EGFR TKI tumor penetrance 
(Figure 12,14). 
It has been previously shown that EDN1 can have differential effects on the blood 
vasculature depending on the tissue in which the tumor arose[69, 84-86]. It has been posed 
by previous researchers that EDN1 concentrations typically secreted by tumor cells may 
not be sufficient alone to overcome the vasoconstrictive effect of EDN1 and cause a pro-
angiogenic effect. Therefore, the contribution of surrounding normal tissue to increasing 
EDN1 concentration cannot be ignored. It may be that in tissues which normally secrete 
high levels of EDN1, tumor cells secreting EDN1 have a pro-angiogenic effect whereas in 
tissues which are normally EDN1 poor, secretion of EDN1 has an anti-angiogenic effect. 
Therefore, a limitation of this study is that it is limited to sub-cutaneous xenograft models. 
The blood vasculature in the subcutaneous space is limited compared to that of the lung. 
Additionally the expression of EDN1 in the lung is known to be higher than that of the sub-





the native environment of the lung, I propose performing an intrapulmonary injection of 
epithelial, mesenchymal and admix tumor cell lines. I hypothesize that in a tissue of high 
native EDN1 expression, the effect of EDN1 may be pro- angiogenic. 
I conclude by hypothesizing a model incorporating the vasoconstrictive properties of 
EDN1 into our observed MVD depression in EDN1-secreting tumors. I believe that in a 
purely epithelial tumor, the secretion of VEGF-A competently induces tumor neo-
angiogenesis leading to tumor growth while maintaining vasodilation in the blood 
vasculature. Upon gefitinib treatment, the dilated properties of the tumor blood vasculature 
allow for the drug to fully penetrate the tumor allowing for maximal efficacy and significant 
tumor reduction. Although I have shown that short-term gefitinib treatment is sufficient to 
induce EDN1 secretion in epithelial cells, I hypothesize that this event does not occur fast 
enough to prevent significant tumor reduction. In a tumor completely composed of 
mesenchymal cells, the lack of VEGF-A secretion prevents tumor neo-angiogenesis while 
the secretion of EDN1 causes existing blood vasculature to become constricted. Together, 
this leads to a relatively small tumor unable to grow above a certain threshold. Upon gefitinib 
treatment, the limited and vasoconstricted blood vasculature results in poor drug penetrance 
leading to the observed drug resistance. In 50/50 admix conditions, the presence of EDN1 in 
the tumor microenvironment leads to vasoconstriction above basal levels while the presence 
of VEGF-A allows for enough tumor neo-angiogenesis to result in overall tumor growth. 
Upon gefitinib treatment, the presence of EDN1-secreting mesenchymal cells cause the 
protection of the epithelial cell component allowing the epithelial cells enough time to switch 
from VEGF-A secretion to EDN1 secretion. This high level of EDN1 secretion is then 





preventing drug penetrance and leading to the observed drug resistance. 
 
 
Figure 15. Model Illustrating Hypothesis Relating EDN1-Mediated Vasoconstriction to 
Drug Resistance and Reduced MVD
 
In summary, angiogenesis in NSCLC has been identified as important therapeutic 
target in combination with EGFR TKIs. However, only small incremental advancements have 





inhibition of VEGF-mediated neovascularization is not therapeutically efficacious. I present 
experimental evidence that a subpopulation of NSCLC cells with EGFR TKI-induced EMT 
contributes toward the attenuation of the response to EGFR TKI therapy. One of the hallmarks 
of cancer is heterogeneity and I have previously demonstrated that tumor heterogeneity 
within NSCLC cells lines harboring EGFR kinase domain mutations gives rise to divergent 
resistance mechanisms in response to treatment. In vivo admix models are instructive in 
studying intratumoral heterogeneity and in elucidating therapeutic responses and tumor-host 
interactions. While NSCLC cells with acquired EGFR TKI resistance and EMT phenotype 
did not exhibit growth advantage in vitro, a 50% epithelial EGFR TKI sensitive and 50% 
mesenchymal EGFR TKI resistant admix provided significant growth advantage in vivo 
assessed by caliper measurement. This preliminary result led us to hypothesize that changes 
in angiogenic growth factor expression during the EMT process might lead to the in vivo 
growth advantage I observed. To test the hypothesis, I utilized the Luminex multiplex assay 
system to quantify secreted growth factors, cytokines, and chemokines important in 
angiogenesis. I have discovered that epithelial EGFR TKI sensitive cells secrete a significant 
amount of VEGF-A and cells with acquired/transient EGFR TKI resistance with an EMT 
phenotype secrete substantial amount of EDN1. Using an in vitro tube formation assay, I 
showed that secreted VEGF-A and EDN1 in admix conditions work synergistically to 
promote endothelial cell differentiation. Furthermore, this synergistic effect can be 
attenuated by VEGFR2/EDNRA dual inhibition. Surprisingly, ectopic overexpression of 
EDN1 in EGFR- mutated HCC827 cells resulted in significant growth retardation in vivo. 
Informed by a literature search, I hypothesized that the presence of EDN1 in the tumor 





vasoconstrictive property of EDN1. I observed that epithelial/mesenchymal admix tumors 
and ectopic overexpression of EDN1 in EGFR-mutated HCC827 cells conferred 
significantly more resistance to gefitinib in vivo. This result led us to hypothesize that the 
vasoconstrictive properties of EDN1 may reduce MVD in EGFR-mutated NSCLC tumors 
leading to poor EGFR TKI penetrance in vivo. I tested this through CD31 IHC staining and 
MVD calculation. I tested poor EGFR TKI penetrance indirectly by examining 
phosphorylated EGFR and found maintenance of the signal in admix and mesenchymal 
tumors. Taken together, I suggest that inhibition of the EDN1 signaling system may be an 
important component to a blood vascular-based approach to treatment of EGFR-mutation 
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